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THERAPEUTIC POTENTIAL OF CURCUMIN IN A SPINAL CORD INJURY
MODEL: LOCAL APPLICATION VERSUS DIETARY SUPPLEMENT

ABSTRACT
Spinal cord injury is a debilitating disability that is characterized by a sequence of tragic
events that occur following the primary impact aggravating the condition, collectively
called secondary spinal cord injury. Oxidative damage and inflammatory surge are two
hallmarks of the secondary spinal cord injury cascade. Curcumin is a polyphenolic
compound extracted from the rhizome of Curcuma longa that has been well known to
possess antioxidant and anti-inflammatory properties. The objective of this study was to
evaluate the potential of curcumin as an antioxidant and anti-inflammatory agent following
spinal cord injury, and to compare its therapeutic effects following local application
directly to the injury versus its effect when given as a dietary supplement in a spinal cord
hemisection model at T9-T10 level of the spinal cord. Female Sprague Dawley rats were
randomized into a control group, injury groups (1 day and 7 days) , local treatment groups
single dose of Curcuma longa extract immediately on the injury site (1 day and 7 days) and
a Dietary supplement group. Crude Curcumin was added to the animals’ feed (10% of daily
feed) one week before and week after injury. Oxidative stress parameters used for detection
the effect of Curcumin before and after treatment were Malondialdehyde (MDA) by
Thiobarbituric acid assay (TBA) and total antioxidant capacity (TAC). Expression of tumor
necrosis factor alpha (TNF α) and interleukin 6 (IL-6) was detected using Enzyme Linked
Immunosorbent Assay (ELISA). Our results show that at 7 days, although Dietary
supplement was effective in increasing TAC levels and lowering TNF α expression levels,
yet it did not affect MDA levels (IL-6 data not measured). Local treatment regimen has
shown to be more effective on all four parameters measured as the 7 days. Our results
demonstrate that local Curcumin application directly on the injury site might be more
efficacious in alleviating oxidative damage and reducing inflammation following spinal
cord injury. Further analysis is needed to evaluate the effect of Dietary treatment regimen
on IL-6 and detect the effect of different Curcumin treatment regimens on other antioxidant and anti-inflammatory markers to investigate the role of curcumin in alleviating
oxidation and inflammation.
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CHAPTER 1: LITERATURE REVIEW

1.1. Spinal Cord Injury
1.1.1 Introduction
Spinal cord injury (SCI) is a debilitating tragic disability that affects a lot of people
worldwide. About 2.5 million people have SCI with about 130,000 new injuries affecting
people annually (Thuret et al. 2006). SCI has been described in an ancient Egyptian
physician textbook called “The Edwin Smith papyrus” since 1700 BC as an “ailment not to
be treated” (Porter, 2001)

It influences not only the life of the individual but also the surrounding family members
socially, emotionally and financially. The cost of being enrolled in a clinical trial per
person is about 50,000 to 100,000 dollars in Europe and United States. On the other hand
the cost of preliminary phase 2 human efficacy trials for a drug is about 5 to 10 million
dollars (Tator, 2006). In Spite of all of this, available treatments give modest benefit that’s
why more effort is needed to come up with more effective SCI treatment regimens (Ali and
Bahbahani 2010)

Many of the complications of SCI are permanent and eventually cause serious
consequences, including; respiratory complications which are a frequent cause of death
after SCI (Berney et al., 2011), Bladder dysfunction (Hagen, 2015), and heterotopic
ossification (HO) (Banovac et al., 2004), which leads to reduction in joint motion range.

Unfortunately, to date the approaches taken to handle or treat SCI can be still regarded as
sedative, or palliative approaches trying to prevent further progression, handle
dysautonomia and complications of loss of sensory abilities and aiming at teaching patients
on how to cope up with their disabilities (Jablonska et al. 2010, Silva et al., 2014).
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1.1.2 Incidence and Prevalence:

In most countries, SCI patients are below 30 years of age (Singh et al., 2014; Rhee et al.,
2013). A higher male to female ratio is demonstrated and traffic accidents were the most
known cause for SCI followed by falls in elderly. The highest SCI prevalence was (906
/million) in the United States of America and lowest (250-280/million) in France and
Finland (Singh and Tetreault et al., 2014).

1.1.3 Anatomy of the Spinal Cord:

The spinal cord extends from the medulla oblongata in the brainstem through the foramen
magnum of the skull till lumbar vertebra L1 in humans or L3 in rats. The spinal cord
provides connection between the brain and the peripheral nerves. It is protected by the bony
vertebral column and by the three meninges namely: Dura, Arachnoid and Pia matter.
Additional protection is provided by the subarachnoid space (between pia and arachnoid)
which is filled with cerebrospinal fluid as well as, the epidural space between dura and
periosteum; which is filled with adipose connective tissue and loose fibrous tissue (Vander
et al., 2001).

The gray matter is located centrally and is composed of neurons, interneurons, dendrites
and cell bodies of motor neurons, glial cells and the entering fibers of the sensory neurons.
The white matter on the other hand is mainly composed of myelinated axons which are
organized in functional groups called tracts; descending to the periphery or ascending to the
brain transmitting information in both sides, as well as propriospinal (local) tracts which
connect and coordinate different levels of the spinal cord. These tracts are regarded as a
crucial communication means between the brain and the spinal cord (Silva et al., 2014).
2

Descending tracts (pyramidal or extrapyramidal) control motor functions as shown in
figure 1. Pyramidal tracts are so named due to the fact that they decussate (cross from one
side to the other) in the medulla. These tracts terminate at the lower motor neurons in the
grey matter of the spinal cord. Extrapyramidal tracts include: rubrospinal, reticulospinal,
tectospinal and vestibulospinal tracts. These tracts are mostly responsible for complex
movements, fine locomotion tuning, reflexes and postural control.

Ascending tracts shown in figure 1 convey information from the periphery to the cerebral
cortex. The dorsal column fibers carry proprioceptive, vibratory senses and fine touch. The
anterolateral system (anterior & lateral spinothalamic tracts) carries crude touch,
temperature and pain. The spinocerebellar tracts aid in fine tuning and coordination of
motor tasks and carry unconscious proprioceptive data (Lee and Thumbikat, 2015).

Crossing of fibers carrying proprioception, motor function and light touch in the medulla
means that the SCI patient will experience an ipsilateral (same side) deficit while
decussation of fibers conveying information for temperature and pain occurs at their
vertebral level of entrance into the spinal cord leading to a contralateral deficit upon injury
(Lee and Thumbikat, 2015).

3

Figure 1: Ascending and Descending tracts of the Spinal Cord. Reproduced from Lee and
Thumbikat 2015 with permission.

Axons of afferent (sensory) neurons enter the spinal cord via the dorsal root with their cell
bodies present in the dorsal root ganglion, while those of efferent (motor) neurons leave the
spinal cord trough ventral roots. Eventually dorsal and ventral roots combine to form the
mixed spinal nerve (motor, sensory and autonomic) which exit from 31 vertebral levels
(Cervical-8, Thoracic -12, Lumbar-5, Sacral-5 and one coccygeal nerve) (Silva et al.,
2014).

1.1.4 Pathophysiology of SCI
1.1.4.1 Primary Injury:
SCI pathophysiology is biphasic in nature entailing a primary and a secondary phase. The
primary mechanical injury leads to a cascade of secondary damage involving vascular,
cellular and biochemical events (Simon et al. 2009; White-Schenk et al., 2015). Traumatic
SCI was classified by Bunge and colleagues as “a contusion with cavity formation, massive
compression or laceration” (Bunge et al., 1997).
4

Vascular ischemia is not an uncommon cause for SCI especially as a surgical complication
during the surgery for aortic aneurysm repair (Hollier et al., 1992) where spinal cord
ischemia might result from prolonged aortic cross clamping or ligation of lumbar or
intercostal arteries causing ischemia (Anwar et al., 2016), that might eventually lead to
paraplegia (Shimizu and Yozu 2011).
This primary phase is marked by a series of events shown in figure 2 as spinal shock,
systemic hypotension, ischemia, damaged plasma membrane and ionic imbalance (Oyinbo,
2011).

Figure 2: Pathophysiology of SCI. . A primary injury caused by impact or compression is
followed by a secondary injury cascade that entails a series of cellular, molecular and
biochemical events that contribute to worsening the primary injury. Reproduced from
Esposito and Cuzzocrea 2011 with permission.

1.1.4.2 Secondary injury:
The secondary injury starts to take over following the primary phase and it can last for
weeks (Wilson et al., 2013), the two major events that largely contribute to the secondary
injury are inflammation and oxidative stress, which lead to necrosis, immune system
response and apoptosis (Johnson et al., 2005), neuro-inflammation, free radicals formation,
breakage of the blood-spinal cord barrier (BSCB), ischemic dysfunction, neuronal injury
5

and glial scar formation which limits the SCI recovery ( Ormond et al., 2014). It also
includes other functional problems, such as bladder, rectal and anal incontinence due to
autonomic dysfunction, neuropathic pain and impotence (Singh and Tetreault et al., 2014).

Unfortunately in most cases the aggravating effects of the secondary injury commence
before expert intervention starts (Oyinbo 2011). That’s why treatment strategies are
focusing on combating this sequence of events (Fehlings and Nguyen 2010), and new
strategies would help enhance axonal regeneration and neuronal function, and restore the
disrupted functions that follow the injury.

Finally the chronic phase commences which may last for years post SCI, causing continued
demyelination, apoptosis and cavitation well as syringomyelia which lead to permanent
neurological impairment (Yiu and He 2006; Oyinbo, 2011).

1.1.5 Main Events in Secondary Spinal Cord Injury

1.1.5.1 Inflammation
Following SCI, the net result of the immune system response through its cellular (immune
cells) and molecular (regulatory proteins) components is inflammation (Oyinbo, 2011).
Immune cells secrete pro-inflammatory cytokines as tumor necrosis factor α (TNF-α),
interleukin 1β and Interleukin-6 increasing the extent of inflammation, to remove cellular
debris, unfortunately, over-activation of this inflammatory response aggravates the injury
and damages the healthy tissues (Oyinbo, 2011).

The role of some immune cells in SCI is regarded as controversial (Donnelly and Popovich,
2008). Macrophages and microglia are thought to be a key component for neural
regeneration while others suggest that these cells are responsible for oligodendrocytes
damage (Merrill et al., 1993), demyelination and neuronal death (Rhoney et al., 1996). The
6

infiltration and activation of glial cells and leukocytes becomes the main source of reactive
oxygen species (ROS) (Bains and Hall, 2012). The inflammatory cascade following SCI is
shown in figure 3.

Figure 3: Inflammatory environment following SCI. The primary injury causes hemorrhage
and increase in vascular permeability. Leukocyte extravasation and infiltration then occurs
breaking up inter-cellular proteins and extracellular matrix. ROS are then released from
activated microglia and leukocytes causing protein modification, lipid peroxidation and
gene expression modulation eventually leading to cellular and tissue damage causing
necrosis and apoptosis in neuronal and glial cells within the spinal cord parenchyma. Yet,
the anti-inflammatory subsets of glial cells and leukocytes potentiate anti-inflammatory
mechanisms .Reproduced from Anwar et al., 2016 with permission.

1.1.5.2 Neutrophils and Macrophages:
Following SCI, neutrophils arrive first at the injury site guided by the vascular endothelial
cells. They enhance recovery by removing tissue debris and microbial invaders, and recruit
macrophages (Kigerl et al., 2006). They also release proteases, free radicals, cytokines, and
7

activate other inflammatory and glial cells ultimately causing neuronal and glial toxicity
and death (Joy et al. 2005, Shamash et al., 2002).

Depletion of neutrophils (Noble et al., 2002), inhibition of their adhesion (Hamada et al.,
1996) or blocking of their related enzyme proteolytic activities (Noble et al., 2002) were
correlated with neuroprotection (Kigerl et al.,2006).

Neutrophils and macrophages synthesize a variety of pro-inflammatory cytokines e.g.
TNF-α and IL-1β as part of their function in normal cellular communication (Probert and
Selmaj

1997) ; however, the sustained release of these molecules in SCI triggers

inflammation and disrupts the cytokine release pattern, potentially exaggerating glutamate
excitotoxicity causing neuronal and oligodendrocyte death (Shamash et al., 2002).

Glutamate is the main excitatory neurotransmitter within the CNS (central nervous system),
and excess amounts of it are normally removed by astrocytes and to a lesser extent by
microglia (Rimaniol et al., 2000). However, after SCI its metabolism by astrocytes is
disturbed and its clearance is prohibited by tumor necrosis factor alpha (TNF-α) or
interleukin 1beta (IL- 1β) (Takahashi et al., 2003). Neurons and oligodendrocytes are
particularly sensitive to glutamate excitotoxicity as they demonstrate high numbers of
glutamate receptors (Oyinbo, 2011). Blocking TNF-α or IL-1β enhances neuroprotection in
SCI, traumatic brain injury (TBI) and stroke models (Sharma et al., 2003). Moreover,
interleukin-6 (IL-6) overexpression was shown to potentiate leukocyte infiltration and
impair both locomotor activity and axonal regrowth (Lacroix et al., 2002).
Stellwagen and colleagues demonstrated that TNF α causes an elevation in α-amino-3hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPARs) specifically non
glutamate (non-GLU2-AMPARs) through tumor necrosis factor receptor 1 (TNFR1)
rendering them more calcium permeable. At the same time TNF α causes fewer expression
of surface gamma-aminobutyric acid (GABAA) receptors, consequently causing alleviation
8

in the inhibitory synaptic strength and enhancing excitotoxicity (Stellwagen et al., 2005).
Potassium (K+) and Calcium (Ca2+) may also have a role in neuronal destruction (Jung et
al., 2013).

Neutrophils and Macrophages also release superoxide and Nitric oxide which both react
and combine releasing the highly toxic species, peroxynitrite (Xiong et al., 2007). After
injury, depolarization causes opening of voltage dependent Ca2+, K+ and sodium (Na+)
channels followed by Ca2+ overload leading to peroxynitrite (PON) derived free radicals
production as shown in figure 4 .These peroxynitrite radicals react with amino acids
causing protein Carbonylation and damage the unsaturated fatty acids causing cellular
damage (Xiong et al., 2007).

1.1.5.3 Lymphocytes:
After injury, Activated Lymphocytes carry out an autoimmune response that exaggerates
the effect of macrophages causing more toxicity to the neurons and damage to the bloodbrain barrier (Sriram and Rodriguez, 1997). T-lymphocytes appear to play a dual role in
injury and repair depending on the surrounding microenvironment and the signals that
recruited them (Trivedi et al., 2006). Chemokines are responsible for T-cell migration and
activity modulation at inflammation sites (Sallusto et al., 2000). Some studies correlated
their activation with increased cytokine release (Jones et al., 2005), fibrosis and scarring
(Wynn, 2004).
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Figure 4: Oxidative damage following SCI. . Calcium overload is caused via glutamate
receptor and voltage dependent channels. Mitochondrial oxygen (O2) uptake causes nitric
oxide synthase (NOS) activation and eventually peroxynitrite radicals are formed causing
damage and promote cytoskeletal proteins proteolysis and neurodegeneration. Reproduced
from Bains and Hall 2012 with permission.

Neuro-antigen reactive T and B lymphocytes that act against myelin protein as Myelin
Basic Protein (MBP) have noticeable pathological potential in Multiple sclerosis (Von
Bũdingen et al., 2001). Transgenic rats and mice vaccinated to enhance MBP-reactive T
cells, were shown to cause axonal impairment and demyelination causing neuronal loss
(Jones et al., 2004).
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Athymic nude (AN) rats manifested better locomotor activity than injured Sprague Dawley
rats (SD) one week post injury in a study aiming at detection of T lymphocyte role in SCI .
Moreover, injured SD rats showed acute elevation in death related genes suggesting a
secondary wave of damage caused by T-cells. This suggests that a combination of T-cell
inhibition and other neuroprotective strategies might have a promising therapeutic potential
(Satzer et al., 2015).

Nevertheless, Schwartz and colleagues propose a protective role for T-cells specifically
reactive to MBP in Lewis rats, in enhanced neuroprotection after spinal cord contusion or
crushing optic nerve injury, but not in complete transaction model (Schwartz and Kipnis
2001).

B-lymphocytes also present in the injury site within hours post SCI and last for up to 1
week (Popovich et al., 2001). Enhanced activation of B cells was also evident following
SCI, with elevated CNS antibodies in the serum of SCI individuals (Hayes et al., 2002) and
in a mouse model of spinal cord contusion injury (Ankeny et al., 2006). B-lymphocytes
also enhanced demyelination in an experimental allergic encephalomyelitis model
(Chavarria and Alcocer Varela 2004).

1.1.5.4 Microglial cells:

Microglial cells exist as two main phenotypes, M1 the pro-inflammatory phenotype and
M2 the anti-inflammatory phenotype which are two polarized states whose activation
depends on external signals (Durafourt et al., 2012). Following SCI, microglia sense the
initiation of tissue damage via toll-like receptors (Heiman et al., 2014), and undergo
morphological changes, they attain an amoeboid morphology rather than the ramified
appearance they maintain in their Quiescent state (Lee et al., 2007; Witcher et al., 2015).
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Following SCI, M1 phenotype is activated and initiates a series of damaging side effects to
neurons, axons, oligodendrocytes (Nguyen et al., 2012). This cascade is mediated through
various signaling pathways, such as, inflammatory cytokines (TNF- α, IL-6) (Pineau and
Lacroix, 2007), ROS (Barger et al., 2007), Chemokines (Mantovani et al., 2004) and
Glutamate (Barger et al., 2007). These cytokines are expressed within two hours following
injury (Pineau and Lacroix, 2007).

Moreover, the M1 phenotype has been found to express cell surface and intracellular
receptors such as, CD45 (lymphocyte common antigen), CD11b (integrin family member)
and inducible nitric oxide synthase 2 (iNOS2) which aids in the pro-inflammatory
mechanism. On the other hand M2 phenotype releases anti-inflammatory cytokines as
interleukin 4 (IL-4), interleukin 10 (IL-10) and interleukin 13 (IL-13) (Witcher et al.,
2015). Thus, it appears that microglia play a vital role in the inflammatory cascade
following SCI that can be either pro inflammatory or anti-inflammatory.

1.1.5.5 Astrocytes and Glial Scarring:
Following injury, the blood spinal cord barrier is disrupted (for up to 2 weeks) as a result of
both mechanical forces and the influx of inflammatory mediators (Renault-Mihara et al.,
2008). The activation and recruitment of astrocytes to the injury leads to reactive
astrogliosis, and glial scarring where astrocytes hypertrophy occurs with the production of
intermediate filaments as glial fibrillary acidic protein (GFAP) and vimentin ( Wilhelmsson
et al., 2004), extracellular molecules such as, chondroitin sulfate proteoglycan (CSPG)
which inhibit axonal regeneration ( Schwab et al., 2006). In this manner, Astrocytes build a
wall around the injury site preventing axonal regrowth as shown in figure 5 (Anwar et al.,
2106).
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Central cavitation takes place days to weeks after the primary SCI (Oyinbo, 2011). It is
manifested by an expansion of the SCI lesion size leading to the formation of a cavity
much larger size than the initial scar (Fehlings and Nguyen 2010).

Reactive astrocytes role is rather confusing. On one hand, they are implicated in tissue
integrity preservation (Faulkner et al., 2004), regulation of excess neurotransmitters
production and in the release of extracellular matrix (Von Boxberg et al., 2006). While, On
the other hand, reduction of reactive astrogliosis by inactivation of CSPG (Menet et
al.,2003) or blocking Calcium channels (Lee et al., 2000), decreases the obstruction of the
glial scar against axonal sprouting and regrowth (Von Boxberg et al., 2006).

Wide arrays of genes are upregulated upon reactive astrogliosis (Zamanian et al., 2012),
e.g. intermediate filament proteins as GFAP, nestin, vimentin, Cytokine, and s100
(Zamanian et al., 2012). These genes are shown to form a complex enhancing damaged
membranes repair (Rezvanpour et al., 2011).

1.1.5.6 Inhibitory Molecules:
Two main groups of molecules inhibit axonal regeneration; the first is the proteoglycans.
These are composed of a protein core linked through four sugar moieties to a
glycosaminoglycan (GAG) chain which contains repeated disaccharide units (JohnsonGreen et al., 1991). These molecules have demonstrated an inhibitory profile following
CNS injury. They are mainly expressed by astrocytes, meningeal cells and oligodendrocyte
precursors (Fawcett and Asher, 1999). They are composed of four main groups; Dermatan
sulphate proteoglycans (DSPGs), Heparan Sulphate proteoglycans (HSPGs), Keratan
sulphate proteoglycans (KSPGs) and Chondroitin sulphate proteoglycans (CSPGs)
(Jhonson-Green et al., 1991). CSPGs are the most studied group and it includes: Brevican,
Aggrecan, Neural/Glial antigen 2 (NG2), Versican, Neurocan and Phosphacan.

13

On one hand, these molecules are important for pathfinding and guidance (Fukuda et al.,
1997), but on the other hand, CSPGs rich areas can inhibit axonal growth (Faissner and
Steindler, 1995).

The second group is the myelin associated molecules. Nogo A is one example of this
group. It is a membrane protein which is expressed by oligodendrocytes and some neurons,
it causes growth cone collapse and growth inhibition, when it binds to its specific receptor
named NgR1 in the neuron's membrane (Schwab, 2004).Another molecule in this group is
the myelin associated glycoprotein (MAG) which is stored in Myelin that surrounds the
CNS axons and is also originally produced by oligodendrocytes (Silva et al., 2014). It is
regarded as one of the strongest inhibitors of white matter regeneration (Silva et al., 2014).

1.1.5.7 Apoptotic cell death:
Cell death after the mechanical trauma to the spinal cord is either due to necrosis which
follows inflammation and cell membrane rupture (Oyinbo 2011), or due to apoptosis
(Johnson et al., 2005), which begins within hours following SCI (Oyinbo 2011).The key
players in apoptosis are caspases (Green 1998). Caspase 8 and 9 are the initiator caspases
(Adjan et al., 2007), leading to further activation of caspase 3 (Wu et al., 2003). This in
turn cleaves several downstream substrates that are crucial for apoptosis (Zhang et al.,
2012). TNF-α acts as a mediator of apoptosis, through its death domain on its surface
receptor TNFR1 (Zhang et al., 2012). However, there are conflicts regarding its capacity as
being both pro and anti-apoptotic (Genovese et al., 2009).

1.1.5.8 Demyelinating Surviving Axons:
Oligodendrocytes cell death by excitotoxicity, apoptosis, inflammatory cytokines and free
radicals can cause demyelination of the axons which survived the initial trauma (Oyinbo
2011) as shown in figure 5. Demyelination is evident in the subacute and chronic SCI
phases (Guest et al. 2005) and it is due to oligodendrocytes loss in white matter rostrally
and caudally weeks post SCI (Grossman et al. 2001).
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1.1.6 Oxidative damage in SCI:
The spinal cord and CNS in general has high lipid content (in Myelin) and high oxygen
need, rendering it easily susceptible to cell damage by lipid peroxidation (Tian et al., 2004).
Following SCI, ROS overwhelm the antioxidant buffering mechanisms causing lipid
peroxidation, cell lysis, and organelle damage and calcium imbalance as shown in figure 6.
Thus antioxidant therapies such as high dose methyl prednisolone (MP) are currently the
only useful medical intervention to enhance neuroprotection in SCI patients (Shan et al.,
2010).

Free radicals cause a chain reaction which starts by absorbing an electron from a lipid
molecule, eventually leading to membrane lysis, necrotic cell death and mitochondrial
dysfunction (Sullivan et al., 2007), with an increase in intracellular calcium levels
activating proteases and consequently breaking down cytoskeletal proteins as shown in
figure 7 (Xiong et al., 2007).

15

Figure 5 : Key players in SCI and glial scar formation. Demyelination, necrosis and axonal
destruction takes place along with recruitment of microglia and astrocytes, leukocytes
(neutrophils, macrophages, lymphocytes, natural killer cells). Reproduced from Anwar et
al., 2016 with Permission.

These lipid peroxidation end products can be inactivated by a number of enzymes as
glutathione-s-transferase, aldehyde reductase and aldehyde dehydrogenase (Ayala et al.,
2014). ROS are also inactivated by other antioxidant defense systems such as glutathione
peroxidase, catalase and superoxide dismutase, and other antioxidant mechanisms as
vitamins A, E, and C , flavonoids and carotenoids as well (Bains and Hall, 2012) .
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Figure 6 : Damage caused by oxidative stress following SCI. Oxidative stress causing
neuronal death through DNA damage, mitochondrial dysfunction, protein aggregation and
apoptosis. This damage can be prevented by phytodrugs. Reproduced from (PérezHernández et al., 2016 with Permission.
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Figure 7: Oxidative damage cascade leading to Calcium influx causes rapid calpain
activation. Excess calcium is taken up by mitochondria elevating mitochondrial nitric oxide
synthase (NOS) which compete for O2 radical forming peroxynitrite (PON). PON derived
radicals partially inhibit calpain initially but then, sustained oxidative stress potentiate
cellular damage outweighs the initial calpain inhibition causing further cytoskeletal
degradation. Reproduced from Xiong et al., 2007 with permission.

1.1.7 Role of TNF alpha following SCI:
Tumor necrosis factor alpha (TNF-α) is one of the most well characterized cytokines.
However, to date there is no obvious agreement or consensus on its role in acute CNS
injury (Oyinbo, 2011). Its levels are elevated following SCI reaching its peak within one
hour after primary injury (Dinomias et al., 2009).Most studies suggest that its production at
the site of injury exacerbates tissue damage in SCI (Pan et al. 2003, Paterniti et al. 2009).
TNF α potentiates Wallerian degeneration of axons and activates recruitment of
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macrophages and Schwann cells at the injury site (Sebastian and Schroeter 2003).It also
increases the level of hyperalgesia and central sensitization through stimulation of synaptic
transmission (Kawasaki et al., 2008).
Yakovlev and Faden showed that TNF-α mRNA levels were elevated 30 minutes following
SCI at the injury site and that the extent of injury was proportional to the level of TNF-α
message (Yakovlev and Faden, 1994). Paterniti et al. demonstrated that elevation of TNF α
in a spinal cord trauma model which was accompanied by an elevation in myeloperoxidase
activity (MPO) – a marker for polymorphonuclear leukocyte accumulation 24 hours post
injury (Peterniti et al. 2009).

1.1.8 Current Interventions in Spinal Cord Injury:
As the primary injury to the spinal cord cannot be prevented it can only be minimized
through surgical intervention by means of surgical decompression or stabilization of the
vertebrae. Currently there are no generalized standards of care regarding decompression
surgery regarding indications and timing of interventions (Li & Walker et al., 2014). Many
questions remain unanswered in this regards, as the optimal timing of intervention to gain
neuroprotective effect or even if the intervention itself is recommended or not (Silva et al.,
2014).
Many strategies have been developed to minimize the extent of secondary injury, and
enhance the therapeutic outcomes. Methylprednisolone is the most widely prescribed
pharmacological agent for SCI yet it is the most controversial. It has many advantages as
its ability to inhibit lipid peroxidation, limit inflammatory response, sustain the bloodspinal cord barrier and enhances blood flow (Tator, 1998). Other approaches include
altering neuro-inflammation by means of immune-modulators such as minocycline
(Schwartz and Yoles 2006) or promoting M2 macrophage phenotype through
administration of granulocyte colony stimulating factor (G-CSF) within 72h following SCI
(Guo et al., 2013).

19

Other mechanisms were adopted to enhance regeneration and myelination following SCI
via creating a more suitable environment for axonal regeneration (Thuret et al. 2006).
Nogo-A suppression (Freund et al., 2006), stem cells (Webb et al., 2010), and human
embryonic stem cells (hESC) derived oligodendrocyte progenitor cells (OPCs)
transplantation (Keirstead et al., 2005). Using Neurotrophins (Sharma, 2007),Autologous
Activated Macrophages (Bomstein et al., 2003), reducing neuro-inflammation (Bracken
2012, Das et al., 2011), preventing free radical damage (Bains and Hall, 2012), and
excitotoxicity (Mazzone and Nistri, 2011), and improving blood flow ( Ritz et al., 2010), as
well as targeting the local immune response (Varma et al., 2013), have all been used
following injury with great variability in improving motor function, decreasing lesion
volume, enhancing axonal regeneration and myelination.

Very few studies were advanced to clinical trial stage, e.g. the Sygen Multi Center Acute
SCI

study,

which

used

variable

doses

(200,

300,

and

600

mg

IV)

of

monosialotetrahexosylganglioside GM-1 for 56 days . This study did not show a significant
clinical efficacy of GM-1 but proposed a trend in favor of (GM-1) regarding American
Spinal Injury Association (ASIA) motor, pin prick and light touch scores, contribution to
neurological recovery and enhancing bowel / bladder function and improving sacral
sensation as well (Chinnock and Roberts, 2005; Geisler et al., 2001). Rho antagonist
(BIOAXONE BIOSCIENCES INC, Cethrin®) is another example for a clinically tested
drug in SCI that was found to enhance neuronal growth (Dergham et al., 2002). Thus more
research and clinical trials are needed to validate the benefit and efficacy of current
proposed treatments for SCI.

1.1.9 SCI Models
Models of SCI aim at simulating human SCI injuries as much as possible (Cheriyan et al.,
2014). The following are some examples of these models shown in figure 8.
Compression and Contusion models:

It induces acute transient SCI via weight drop

apparatus, air gun devices, or electromagnetic impactors (Cheriyan et al., 2014). This
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model is clinically relevant as most of human SCI are caused by rapid movements, bone
fractures and consequent impact of bone fragments (Allen, 1911). It is characterized by
rostral and caudal spread of tissue damage from lesion epicenter, disruption of white matter
axons and cell death of grey matter neurons, intra-parenchymal hemorrhage, glial
activation, macrophage recruitment and oligodendrocyte apoptosis (Anwar et al., 2016). In
some cases contusion is followed by sustained compression of the spinal cord.
Experimentally this is simulated through clip compression (Rivlin and Tator 1978), balloon
compression (Vanický et al., 2001) or calibrated forceps compression (Plemel et al., 2008).
It induces vascular derangements, ischemia and hemorrhagic necrosis (Anwar et al., 2016).
Distraction model: it entails stretching of the spinal cord to induce tension forces that
mechanically tear the spinal tissues leading to SCI (Silberstein and McLean 1994).
Dislocation: Involves displacement of the vertebra causing trauma to the cord which leads
to astrocytic activation, vascular impairment in grey matter and apoptosis (Anwar et al.,
2016). No surgical exposure is needed for this type of SCI model; however, more research
is required to validate its reproducibility (Cheriyan et al., 2014).

Transection models: Complete or partial transaction is not regarded as clinically pertinent
models; however, they have been vastly used to study neuronal outcomes following injury
(Chriyan et al., 2014). These models are useful in studying axonal degeneration and
regeneration following SCI (Anwar et al., 2016).

Chemical model: Such as injection of phopholipase A2 to induce inflammation (Liu et al.,
2006), or inducing oxidative damage through injection of hydroxyl peroxynitrite into the
rat’s gray matter. (Bao et al., 2003)
Ischemia reperfusion injury: induced by aortic cross clamping causing neuronal and
vascular damage, it is regarded as a non-reproducible model (Anwar et al., 2016).
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Figure 8 : Different models of rat SCI. . Reproduced from Anwar et al., 2016 with
Permission.

1.2 Curcumin
Phytodrugs represent an important approach in CNS disorders due to their neuroprotective
abilities. Many plants’ raw extracts or their pure isolated compounds have demonstrated
effective neuroprotective properties in neurodegenerative diseases (Pérez-Hernández et al.,
2016). Silymarin administration (400mg/kg/day for 3 days) increased glutathione and
superoxide dismutase (SOD) levels in aged rats brains (Galhardi et al., 2009). While daily
doses (15 mg/kg) of Vincamine in rats reduced iron levels by 50% thus reducing oxidative
stress resulting from iron deposition in neurodegenerative diseases (Fayed, 2010).
Resveratrol a Mediterranean traditional phytophenol present in grapes has also shown
neuroprotective traits. In focal cerebral ischemia model resveratrol significantly minimized
infarction size suggesting a potent neuroprotective effect due to its antioxidant, anti-platelet
and vasodilating effect in focal cerebral ischemia model (Huang et al., 2001).
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Gingerol, a compound of Ginger which is extracted from the root of Zingiber officinale
was shown to inhibit LPS induced cyclooxygenase 2 (COX-2) level of expression in U937
cells subjected to lipopolysaccharides , thus suggesting a role as an anti-inflammatory
inhibiting prostaglandin E2 (PGE2) (Lantz et al., 2007).
Curcumin was first isolated by Vogel and Pelletier in 1815 in an impure form, later on both
its chemical structure and synthesis were confirmed in 1910 and 1913 by Lampe et al. The
first study for its use in human disease was published in 1937 (Oppenheimer, 1937).
Throughout the last 60 years, over 3000 studies have described its variable biological
activities as an antioxidant, antifungal, antibacterial anti-proliferative, pro-apoptotic,
antiviral

and

other

activities,

consequently

exhibiting

medicinal

benefit

in

neurodegenerative diseases, cardiovascular diseases, diabetes , psoriasis and lung fibrosis
and other diseases (Aggarwal and Harikumar, 2009). This pleiotropic nature of curcumin
has been attributed to its ability to interact with multiple targets including inflammatory
cytokines, growth factors, transcription factors, apoptosis related proteins, adhesion
molecules, kinases and others (Zhou et al.,2011).
Curcumin is a bis α, β unsaturated β diketone. Curcumin is one of turmeric constituents.
Turmeric powder consists of 4% curcuminoids, 70% carbohydrates, 6%proteins, 5% resins,
4% fat and 10% moisture as shown in figure 9. Curcumin has also been used over the past
centuries in Ayurveda or Ayurvedic medicine where it showed a great therapeutic efficacy
in different respiratory conditions, liver disorders, diabetic wounds, anorexia and
rheumatism (Araujo and Leon 2001). In Chinese medicine it has been used for abdominal
pain (Aggarwal, Takada & Oommen, 2004) while in Hindu medicine it was applied for
swellings and sprains (Araujo and Leon 2001). In the Orient it was mainly used as an antiinflammatory (Aggarawal et al. 2003).

Many other therapeutic effects of Curcumin have been documented, such as its role as an
antioxidant ( Liu et al., 2013 ; CONEAC et al., 2017), anti-inflammatory (Machova et al.,
2015; Gokce et al., 2016), hepatoprotective (Palipoch et al., 2014), anticarcinogenic ( Rao
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et al. 1995), hypoglycemic (Chuengsamarn et al., 2012), renoprotective (Ueki et al., 2013),
in cardiovascular diseases (Ahuja et al., 2011) and anti-arthritic (Dcodhar et al. 2013).
Studies show that Curcumin can promote neurogenesis in the adult hippocampus (Kim et
al. 2008), inhibition of astrocyte expression, and preventing death of hippocampal cells by
Kainic acid (Shin et al. 2007). Curcumin is characterized by a good safety profile
demonstrated in animal (Qureshi et al. 1992) or human studies (Lao et al. 2006).

Figure 9 : Composition of turmeric powder. . Curcuminoids constitute about 5 % of
turmeric components while the major constituent of turmeric is carbohydrates (70%)
Reproduced from Farooqui 2013 with Permission.

1.2.1 Curcumin Structure:
The main constituents of commercially available curcumin are; Curcumin I (77%),
Curcumin

II

called

demethoxycurcumin

(17%)

and

Curcumin

III

called

bisdemethoxycurcumin (3%) as shown in figure 10, where these curcuminoids collectively
are found in 3-5% of Turmeric (Goel et al. 2008). This yellow complex has multiple
names, e.g. yellow ginger, Indian saffron, yellow root or kacha haldi.
Curcumin powder is soluble in organic solvents as dimethyl sulfoxide, ethanol and acetone
but insoluble in water or ether, it has a melting point of 183 οC, a molecular weight of
368.37 g/mol and a molecular formula of C21H20O6 (Goel et al. 2008).
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Curcumin is more stable at acidic PH while unstable at basic and neutral PH where it is
degraded to ferulic acid and feruloylmethane .If placed in phosphate buffer systems of PH
7.2, it is degraded rapidly within 30 minutes (Wang et al., 1997).

Figure 10 : Different chemical structures of Curcuminoids. Curcumin I compose about
(77%) of the total curcuminoids, Curcumin II (demethoxycurcumin) and Curcumin III
(bisdemethoxycurcumin) are present in smaller ratios. Reproduced from Farooqui 2013
with permission.

Curcumin degradation is slow at PH 1-6 which mimics the stomach PH. While one of the
major Curcumin metabolites called tetrahydrocurcumin is more stable at neutral or basic
PH (Pan et al. 1999), keeping its antioxidant abilities (Somparn et al., 2007).

Curcumin has shown to exhibit poor bioavailability for three main reasons: its poor
absorption, rapid metabolism in the liver and rapid systemic elimination due to its short
half-life (Bisht and Maitra 2009). Curcumin has shown to be highly tolerable. Phase 1 and
2 clinical trials of Curcumin have been carried out on patients with advanced colorectal
cancer for 4 months at variable doses (500, to 12000 mg/day) showed no toxicity (Cheng et
al. 2001). It showed that the serum concentration peaks at 1-2 hours following oral intake
of Curcumin, followed by gradual decline within 12 hours (Jiao et al., 2009).
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Curcumin metabolites do not have the same power or activity as the parent molecule where
it has been reported that the reduced or conjugated forms of Curcumin do not have the
same inhibitory effect on inflammatory enzymes expressed in human colon cells culture
(Ireson et al. 2001).

To make the best use of its therapeutic properties, many approaches have been proposed to
enhance Curcumin’s bioavailability, e.g. using an adjuvant as Piperine which interferes
with the process of glucuronidation in the liver and intestinal metabolism, and complexing
Curcumin with phospholipids. (Indena, Meriva®) - A phosphatidylcholine-Curcumin
complex- showed plasma concentration and area under the curve (AUC) were 5 times
higher than free Curcumin (Marczylo et al., 2007), hence showing an enhanced
bioavailability pattern.

Also, preparing Curcumin liposomes and nanoparticles have been reported to remarkably
increase free Curcumin’s bioavailability (Gota et al., 2010). Where mean peak plasma
concentration of 650 mg of solid lipid Curcumin nanoparticle (SLCP) was 22.43 ng/ml
while the same quantity of the unformulated Curcuminoid extract (95%) was undetectable;
however, the study reported remarkable inter-individual variability in the two tested groups
proposing complex absorption kinetics (Gota et al., 2010).

1.2.2 Curcumin as an Antioxidant and Anti-Inflammatory:
Curcumin is a highly pleiotropic molecule that affects variable molecular targets involved
in neuro-inflammation, oxidative stress and neuroplasticity (Farooqui 2010). Curcumin
possesses anti-inflammatory and anti-oxidative powers by downregulating enzymes as
lipoxygenase (LOX), COX2 and inducible nitric oxide synthase (iNOS), these enzymes
enhance the generation of several inflammatory mediators as leukotrienes, cytokines and
TNF α (Farooqui et al. 2013).
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Curcumin was shown to protect biological membranes including neural membranes against
peroxidative damage, due to its ability to scavenge free radicals resulting from peroxidation
(Menon and Sudheer, 2007). This unique ability is due to the presence of functional groups
including carbon-carbon double bonds, β diketo group and phenyl rings to which hydroxyl
and methoxy groups are attached (Menon and Sudheer, 2007; Indira Priyadarsini et al.,
2003). This remarkable antioxidant capability is comparable to Vitamin E (Nimse et al.,
2015)

A study was performed to evaluate the antioxidant potential of Curcumin in rat SCI model
demonstrated that SOD level was higher in the Curcumin group compared with MP group.
Malondialdehyde (MDA) exhibited the lowest levels in Curcumin group. It was concluded
that Curcumin exhibits an antioxidant capacity against oxidative damage following SCI
(Kavakli et al., 2011)

Neuro-inflammation is a natural defense mechanism aiming at isolating the injured tissue
from the healthy tissue; unfortunately it might cause the destruction of the injured and
healthy tissues (Correale and villa 2004). Upon CNS injury, the main mediators of
inflammation are astrocytes and microglial cells. Upon injury, these cells enhance the rapid
release of a number of cytokines/ chemokines which degrade the neural membrane, help
release arachidonic acid and lyso-phosphatidylcholine (Farooqui 2013). Arachidonic acid is
consequently oxidized to the pro-inflammatory eicosanoids as prostaglandins, leukotrienes,
and

thromboxanes

by

the

help

of

COX

and

LOX.

On

the

other

hand,

lysophosphatidylcholine enhances the synthesis of the pro-inflammatory platelet activating
factor. Thus this cascade of events intensifies an aggressive neuro-inflammatory process
(Farooqui 2013).

Inflammation is finally terminated by a process of resolution through the release of antiinflammatory mediators as IL-10, resolvins, protectins and lipoxins (Farooqui 2010) and
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this process is a turning-off mechanism held by neural cells for the purpose of limiting
tissue injury (Farooqui 2013).

Curcumin has displayed a remarkable anti-inflammatory potential. It decreases linoleic acid
conversion to arachidonic acid (Farooqui 2013). It also blocks the ability of macrophages
to uptake arachidonic acid therefore limiting its ability for eicosanoids production.
Curcumin can also inhibit cyclooxygenases and lipoxygenases and thus inhibit
prostaglandins and leukotrienes synthesis (Rajasekaran, 2011).

Previous studies also demonstrated that dietary Curcumin decreased phospholipase A2,
phospholipase C and prostaglandin E2. Moreover products of the lipoxygenase and
cyclooxygenase as prostaglandin E2 and 15 (S) hydroxyeicosatetraenoic acid from
arachidonic acid was reduced in colonic mucosa and tumors in Curcumin fed animals
versus control group (Rao et al., 1995).

Curcumin also showed the ability to decrease COX at the transcriptional level. A study by
the American Association for cancer research (AACR) on human colon cancer cells
concluded that Curcumin reduced COX-2 expression on the mRNA level in a time and
dose dependent manner and inhibited cell growth as well (Goel et al. 2001).

1.2.3 Molecular Targets of Curcumin:

Curcumin has proved to be a highly pleiotropic molecule that can interact with multiple
molecular targets. Curcumin can bind directly to these targets or act indirectly through
modulation of their activities (Zhou et al., 2011).

From the proteins that act directly with Curcumin: DNA polymerase (Takeuchi et al. 2006),
lipoxygenase (Skrzypczak et al. 2003) and tubulin (Gupta et al. 2006). It has been proven
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that Curcumin can bind to different divalent metal ions as well as Fe, Cu, Mn and Zn
(Ishihara and Sakagami 2005).

Curcumin might activate or attenuate the activity of different transcription factors
depending on the particular target. For instance, a Curcumin analogue has shown an ability
to suppress the activity of nuclear factor kappa B (NF-KB) by inhibiting its nuclear
translocation in Mouse RAW 264.7 and its downstream inflammatory cytokines as tumor
TNF α , Interleukin 1β (IL-1 β) and interleukin 6 (IL-6) in macrophage cells and it was
found to be even more potent than Curcumin (Olivera et al., 2012). Therefore, inhibiting
the activation of many genes responsible for proliferation and cell survival as Cyclin D1,
IL-6, COX-2 and matrix metallopeptidase (MMP 9) , thus arresting the cell cycle, induces
apoptosis and inhibiting cell proliferation (Aggarwal &Takada et al., 2004; Wang et al.,
2015).

Curcumin loaded solid-lipid nanoparticles reduced the expression of pro-inflammatory
cytokines in serum as TNF-α, IL-6 and IL-1β, increased expression of anti-inflammatory
IL-10 cytokine (Wang et al., 2015).

In a study that aimed at revealing the key players behind the anti-inflammatory mechanism
of Curcumin, Curcumin suppressed COX-2, inducible nitric oxide synthase (iNOS)
mediators of inflammation. The study suggested that this effect was in part due to Janus
Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) inflammatory
cascade inhibition in the brain microglial cells (Kim et al., 2003). Curcumin also
suppressed (STAT-3) phosphorylation significantly and showed anti-proliferative effect
assessed by Cyclin D1 in lung adenocarcinoma cells (Alexandrow et al., 2012).
Peroxisome proliferator- activated receptor gamma (PPAR-ɣ) is a member of a large and
diverse group of proteins factors called the nuclear receptor family of transcription factors.
It regulates different functions as inflammation, apoptosis, cell differentiation and lipid
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metabolism (Farooqui 2013). Its main role is to downregulate macrophage, microglial
activation and cytokine expression by inhibiting the activity of some transcription factors
as NF- kB, activator protein 1 (AP-1) and STAT proteins (Ricote et al. 1998; Aggarawal et
al., 2007). Xu et al have shown that Curcumin induces PPAR-ɣ gene expression in
activated hepatic stellate cells (HSCs) (Xu et al., 2003). In another study, Curcumin
activated PPAR-ɣ cells inhibited Moser cells (human colon cancer cell line) and could
suppress cyclin D1 and epidermal growth factor receptor (EGFR) gene expression (Chen
and Xu 2005).

The limited regenerative ability of the injured axons following damage or injury to the
brain and spinal cord in the adult mammalian CNS is due to the inhibitory effect of various
neurite outgrowth inhibitors at the injury site consequently impairing axonal regeneration
and causing functional deficits (Kohta et al., 2009). Besides the myelin associated
inhibitory molecules, extracellular matrix molecules also play a growth impeding role as
well. Astrocytic activation and the release of extracellular matrix inhibitory molecules as
CSPGs (Kohta et al., 2009), causes further impediment to axonal regeneration (Yamashita
et al., 2005; Yiu and He, 2006).
Zheng and Chen concluded that Curcumin could enhance PPAR-ɣ activity in HSCs thus
inducing apoptosis and suppressing cell proliferation and extracellular matrix (ECM) gene
expression. They also concluded that PPAR-ɣ activation by Curcumin could interrupt
transforming growth factor (TGF-β) pathway leading to the inhibition of connective tissue
growth factor (CTGF) expression which is originally responsible for ECM overproduction
(Zheng and Chen, 2006). Yuan et al. also demonstrated a correlation between TGF-β
inhibition by Curcumin and decreasing the deposition of CSPG of the extracellular matrix,
reducing glial scar formation and enhancing innervations in SCI (Yuan et al. 2015), this
renders the environment more suitable for axonal regeneration following injury.
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Nuclear factor E2 related factor-2 (Nrf2) is a transcription factor that controls basal levels
of expression of a number of antioxidant genes as well as enhancing the expression and
upregulation of a number of detoxifying, antioxidant and cytoprotective genes that reduce
tissue injury (Element 2004). Moreover, it is proposed that Nuclear Factor E2 Related
Factor-2/ Antioxidant Response Element (Nrf2/ ARE) activation within the astrocytes
enhances neuroprotection to neurons through mediating the expression of genes essential
for maintaining redox potential and scavenging of free radicals (Kraft et al. 2004).

Curcumin leads to increasing Nrf-2 level thus enhancing its binding to ARE and increasing
the expression of heme – oxygenase 1 (HO-1) in both neural and non-neural cells through
activating UDP-glucuronosyltransferase (UGT) which is responsible for detoxification of
many toxins present in our daily diet where HO-1 plays a pivotal role in cytoprotection
from toxins of either endogenous or exogenous origin thus enhancing neuroprotection
(Hatcher et al. 2008; Scapagnini et al., 2011).

Growth factors together with their receptors play a crucial role in the normal differentiation
and growth process. Any irregularities in these molecules function or expression can cause
abnormalities in development which might lead to malignant transformation (Witsch et al.,
2010). Curcumin can regulate the expression of these growth factors thus demonstrating
anti-invasive, anti-proliferative and anti-angiogenic effects (Zhou et al., 2011).

The epidermal growth factor receptor (EGFR, ErbB, and Her 1 in humans) is an integral
protein kinase of the plasma membrane that comprises multiple autophosphorylation sites
(Scaltriti and Baselga 2006). It was recently demonstrated that EGFR inhibition blocked
pro-inflammatory cytokine secretion from reactive astrocytes and inhibited reactive
astrogliosis as well in a scratch wound model in vitro, and reduced neuronal loss and
demyelination which was concurrent with improvements in hind limb motor function and
in bladder function as well in SCI rat model, thus proposing that EGFR inhibition might be
a promising potential after CNS injury (Li & Li et al., 2014). Thus, if Curcumin has an
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inhibitory effect on EGFR, this might provide a new mechanism of how Curcumin can
impede the undesirable effects of reactive astrogliosis and enhance axonal regeneration.

In human astroglioma cell lines, Curcumin strongly suppressed phorbol 12-myristate 13acetate (PMA) induced phosphorylation of extracellular signal–regulated kinases (ERK) ,
c-Jun N-terminal kinase (JNK) and p38 mitogen activated protein Kinase (MAPK) thus
suppressing MMP-9 enzymatic activity, mRNA and protein level as well as shown in
figure 11 (Woo et al.,2005). This suggests that Curcumin can suppress AP-1 and NF-KB
through inhibiting MAPKs pathway consequently adding to Curcumin’s potent anti-cancer
and anti-inflammatory effects (Zhou et al. 2011).

Figure 11 : Curcumin effect on MAPK signaling pathway in human astroglioma cells. The
figure shows MMP-9 signaling pathways in PMA treated U87MG cells. Curcumin inhibits
(PMA) induced phosphorylation of ERK, JNK and p38 MAP kinase thus suppressing
(MMP-9) enzymatic activity, mRNA and protein level, Reproduced from Woo et al., 2005
with permission.

Pro-inflammatory cytokines as TNF-α, IL-1β and IL-6 are molecules produced excessively
after severe injury or infection and they participate significantly in the development of
systemic and local inflammation which might result in organ failure (Munford and Pugin
2001). The gene and protein cytokine expression is tightly regulated in the producing cells,
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and one of the critical steps in this regulation is gene transcription, thus manipulating and
regulating some of the transcription factors as NF-KB is a suggested strategy in controlling
the inflammatory response (Baeuerle and Henkel 1994). Several research groups have
demonstrated the ability of Curcumin to act as a potent anti-inflammatory by modulation of
various inflammatory cytokines production (Chen et al., 2008). Both in vitro and in vivo
studies have shown that Curcumin has a profound inhibitory effect on TNF-α production
(Zhou et al., 2011). Curcumin prevented the release of pro-inflammatory cytokines, PGE2
and nitric oxide (NO) in a dose dependent manner. Curcumin also attenuated inducible NO
synthase and cyclooxygenase-2 expression on mRNA and protein levels (Park, 2007).

Another group of inflammatory cytokines are the interleukins which play a crucial role in
the regulation of the inflammatory response and in the signaling pathways as NF-kB and
STATs which are involved in angiogenesis and tumor invasion (Dinarello, 2006). In an
experiment done on TNF-α treated cells, Curcumin could attenuate expression of TNF α
induced interleukin 1β (IL-1β) and interleukin 6 (IL-6) by inhibiting activation of NF-kB
and MAPKs pathway (JNK, p38, MAPK, ERK) (Cho et al., 2007). A summary of
Curcumin various targets is highlighted in figure 12.
Curcumin is able to form chelates with transition metals due to the presence β unsaturated
β-diketone moiety. Metal chelates of Curcumin with Cu2+ , Fe2+ , Mn2+ , Pb3+ Have been
reported (Gupta et al., 2011). A study showed that Curcumin mononuclear complex with
copper has anti-oxidant properties superior to Curcumin. The complex protected the cells
against superoxide dismutase and glutathione peroxidase initially induced by radiation
(Kunwar et al.,2007).Manganese complexes with Curcumin and its derivatives showed a
potential capacity of protecting brain lipids from peroxidation (Sumanont et al., 2004).

Curcumin was found to bind to DNA via guanine and adenine N7 (major groove) and
thymine O2 (minor groove) and to the phosphate (PO20 backbone as well. Curcumin
binding to RNA was through H-bond to uracil O2 besides guanine and adenine N7 binding
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as well as to the phosphate backbone (Nafisi et al., 2009). Further investigation is needed to
explore the outcomes of Curcumin DNA binding especially regarding its noticeable nuclear
localization and presence in tumor cells (Gupta et al., 2011).

Figure 12 : Molecular targets of Curcumin. Curcumin can either upregulate or down
regulate various molecular targets as Nrf2 and NF-kB respectively inducing a number of
biological effects as antioxidant and anti-inflammatory. It also targets a number of
cytokines, enzymes and growth factors affecting several biological processes. Reproduced
from Shen et al., 2013 with permission

The role of Curcumin with DNA and other molecules still looks confusing and definitely
more investigation in this arena is a necessity to clarify exactly the risk benefit ratio of
Curcumin as a therapeutic agent either alone or in combination.
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STUDY OBJECTIVES
The aim of this study is to investigate the role of Curcumin on the inflammatory and
oxidative components of the secondary injury cascade following primary SCI in a rat
model. We specifically aimed at comparing the effect of local application of Curcumin
directly on the injury site with that of Dietary Curcumin supplement, by comparing the
change in oxidative stress and inflammatory markers before and after Curcumin treatment.
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CHAPTER 2: Materials and Methods

2.1 Establishment of SCI model:
A randomized controlled animal study using Female Sprague Dawley rats weighing
approximately 150gm-200 gm were purchased from Ain Shams University, Cairo. The
animals were allowed free access to food and water before surgical procedures. All
experiments were performed according to the NIH (PHS Policy on Humane Care and Use
of Laboratory Animals, 2015 (US Department of Health and Human Services 2015) and
international guiding principles for biomedical research involving animals December 2012.
All rats were anesthetized with ketamine (75 mg/kg) intraperitoneally. After shaving and
cleaning the skin with Betadine, skin and muscle incision was made over the mid-dorsal
section of the back. Laminectomy was performed at T9-T10 thoracic vertebral levels. The
dura was incised longitudinally and spinal cord injury was performed by right side lateral
hemisection using micro-iris scissors at T9-T10 level, Tail wagging reflex and hindlimb
retraction proposed successful model establishment. Muscles and skin were then sutured in
layers. All animals received analgesia (Voltaren 15 mg/kg) and local with systemic
antibiotics (10 mg/kg) (Nair et al., 2016) were given post injury to prevent either surgical
or urinary tract infections. Bladder evacuation was performed as needed during the
experiment.
Two time points were investigated at our study and animals were grouped as follows::
● Control group n=15 normal rats and n=15 sham surgery rats (skin and muscle
incision with no injury to the cord).
● Two Injury groups n=15 (at each time point) with lateral hemisection level at days 1
and 7 (SCI 1d and SCI 7d)
● Two local treatment groups n=15 (at each time point) with Curcumin (Curcuma
longa extract, Herb Pharm, Williams, OR) 200 mg/kg single dose (Yuan et al.,
2015) at the injury site immediately after injury (SCI+CUR 1d and SCI+CUR 7d)
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● Dietary supplement group n=15 (SCI+ Diet 7d) where crude Curcumin (Imtinan,
Egypt) was mixed with diet for one week before and one week after injury as 10%
of daily feed.
At the time of analysis, an average of 4-6 rats were used for each marker where rats were
sacrificed with IP ketamine overdose after 1 day or 7 days for sample collection, the spinal
cord was exposed at the injury site where a segment including the injured area was
removed and properly preserved.

2.2. Oxidative Stress Parameters:
2.2.1 Malondialdehyde test by Thiobarbituric Acid Assay

Malondialdehyde (MDA) is an end product of lipid peroxidation. The level of
Malondialdehyde

was

determined

using

Thiobarbituric

acid

(TBA)

assay

(BIODIAGNOSTIC). TBA reacts with Malondialdehyde (MDA) at 95°C for 30 minutes
forming a colored reactive product that can be measured.
Spinal cord samples were homogenized in ice cold Phosphate buffered saline (PBS, pH
7.4) supplemented with protease cocktail inhibitor (Sigma-Aldrich). Samples were
centrifuged at 10000 g for 15 minutes at 4°c. The supernatant was then removed to be used
in the assay at -80 °c. Thiobarbituric acid (TBA) reacts with malondialdehyde (MDA) at
95°C for 30 minutes forming a reactive product of a pink color that can be measured at 534
nm.so samples were incubated with TBA for 30 minutes in boiling water and absorbance
was measured at 534 nm. Samples were run in duplicates. MDA is expressed as nmol/
gram wet tissue.
2.2.2 Total Antioxidant Capacity:
The total antioxidant capacity in spinal cord samples (TAC) was determined using
colorimetric assays (BIODIAGNOSTIC). This test is used as a measure of the ability of
antioxidant systems in a sample to buffer increased reactive oxygen species (ROS).
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The principle of the test is that exogenous H2O2 is added where a part of it is removed by
the power of the antioxidants in the sample and the residual amount is determined in a
colorimetric manner through an enzymatic reaction that converts 3,5,dichloro -2hydroxybenzene sulphonate into a colored product.

Spinal cord tissue samples were homogenized in ice cold Phosphate buffered saline (PBS,
pH 7.4) supplemented with protease cocktail inhibitor (Sigma-Aldrich). On performing the
assay samples were centrifuged at 10000 g for 15 minutes at 4°c. The supernatant was then
removed to be used in the assay at -80 °c. Samples were run in duplicates. TAC is
expressed as mM/L. TAC and MDA assays were analyzed at Cairo University Research
Park, Faculty of Agriculture, Cairo University using STAT LAB SZSL60-Spectrum.

2.3 Inflammatory Markers Testing by Enzyme Linked Immunosorbent Assay
(ELISA):
Spinal cord samples (including the injury epicenter) were homogenized using ice cold PBS,
PH7.4 supplemented with protease cocktail inhibitor (Sigma -Aldrich) and centrifuged at
10000 g for 15 minutes at 4°c. The supernatant was then removed to be evaluated for
TNF-α enzyme linked immunosorbent (ELISA) assay kit (WKEA MED SUPPLIES
CORP, New York, USA), and IL-6 ( R&D systems, R6000B ) according to the
manufacturer’s guidelines.
Briefly, the microplate is coated with an antibody specific to TNF α or IL-6 Standard
dilutions were prepared according to the manufacturer’s guidelines, samples were diluted
1:5 using calibrator diluent, wells were washed and conjugate ( HRP enzyme catalyzed
conjugate) was added followed by incubation. Finally substrate solution was added and
incubated followed by stop solution where OD readings were determined. All samples were
run in duplicates. Finally, the concentrations of the samples were calculated from the
constructed standard curve represented as Pg/ml.
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2.4 Neurological evaluation
In our study, a neurological assessment using modified Tarlov Criteria (Shi et al., 2010)
was performed. The criteria were as follows: 0 (no movement), 1 (minimal movement), 2
(good movement), 3 (stand and walk but cannot hop) and 4 (normal). A behavioral
assessment using the grid walk (sensorimotor test) and the inclined plane test (motor test)
was also conducted by 7 days treatment compared to simple injury group.
2.5 Histological Staining
Following anesthesia, rats were sacrificed and the spinal cord sections surrounding the
injury epicenter were removed, dehydrated, embedded in paraffin and cryosectioned into 5
μm thick sections. Pathologic changes of the spinal cord were detected using hematoxylin
and eosin staining. Histological examination of spinal cord sections for local treatment and
dietary treatment groups to be completed.

2.6. Statistical Analysis:

All results were tabulated and statistical analysis was performed using IBM SPSS program
(SPSS Inc., Chicago, IL, USA) , version 20, and all graphs were done using Microsoft
Excel 2010. Quantitative data was represented as Mean ± Standard Deviation.
One-way ANOVA test was used to compare means of quantitative variables. If ANOVA
test was positive, Dunnett post Hoc test was used to identify the variable that made the
significant change. Independent t-test was used to compare means of quantitative variables
within SCI and SCI+CUR groups. All p-values are two-sided, and difference was
considered statistically significant if p≤0.05 (95% confidence interval).
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CHAPTER 3: RESULTS

3.1 Effect of Local and Dietary Curcumin on Oxidative Stress Markers in Spinal
Cord Tissue
To study the effects of Curcumin on oxidative damage following SCI, we measured MDA
and TAC levels in spinal cord tissue at 1 and 7 days post injury after local treatment (200
mg/kg) with Curcuma longa extract (Herb pharm, Williams, Oregon). For the dietary
supplement with crude Curcumin MDA and TAC levels were measured only at 7 days post
injury.
In this section results are demonstrated for:


1 day after SCI: Control group, Injury (SCI group) and Local treatment group
(SCI+CUR).



7 days after SCI: Control group, Injury (SCI group), Local treatment group
(SCI+CUR) and Diet Supplement group (SCI +Diet).

Groups will be referred to as Control, injury (SCI), local treatment (SCI+CUR) and Dietary
supplement (SCI + Diet).

3.1.1 Local Curcumin Significantly Decreases MDA Levels 1 Day after SCI
Malondialdehyde (MDA) was measured in spinal cord tissue samples in all groups; control,
injury at 1 and 7 days (SCI 1 day and 7 days), local treatment (200 mg/kg SCI + CUR 1
day and 7 days), and Dietary supplement group (SCI+ Diet) using Thiobarbituric Acid
assay (TBA) assay and expressed as nmol/g wet tissue. As shown in figure 13, 1 day after
SCI, MDA levels in SCI group were significantly elevated compared to control group (P <
0.01). Following local treatment (SCI+CUR), MDA levels were significantly lower when
compared to SCI group p<0.05. Tables are represented in appendix.
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3.1.2 Local Curcumin Significantly Decreases MDA levels 7 Days after SCI

At day 7 following local treatment (SCI+CUR), MDA levels were significantly lowered
when compared to SCI p< 0.05. However, diet supplement (SCI +Diet) did not induce a
significant reduction in MDA levels when compared to SCI group as shown in figure 14.
Tables are represented in appendix.

MDA Levels in Spinal Cord Tissue - 1 Day
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Figure 13: MDA levels in spinal cord tissue 1 day after SCI. MDA levels for Control, SCI,
SCI+CUR in homogenized spinal cord tissue. MDA represented as nmol/g wet tissue
weight. n = (4-6), all samples were run in duplicate. Error bars are standard deviation
(**p<0.01 vs. control group and # p<0.05 vs. SCI group). (One way ANOVA, Dunnett post
hoc, Independent t-test).
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MDA Levels in Spinal Cord Tissue - 7 Days
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Figure 14 : MDA levels in spinal cord tissue 7 days after SCI. MDA levels measured for
Control, SCI, SCI+CUR and SCI+Diet groups in homogenized spinal cord tissue. MDA
represented as nmol/g wet tissue weight. n = (4-6), all samples were run in duplicate. Error
bars are standard deviation (#p<0.05 vs SCI group). (One way ANOVA, Dunnett post hoc).
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3.1.3 Total Antioxidant Capacity 1 Day after SCI and Local Curcumin Application
Total antioxidant capacity (TAC) was measured to detect the effect of Curcumin as an
antioxidant following SCI. TAC was measured as mM/L of homogenized tissue samples.
An elevation in TAC might be an indication of an antioxidant capacity exerted by
Curcumin treatment. As shown in figure 17 at day 1 after SCI, TAC levels were
significantly lowered in all injury and treatment groups compared to control p < 0.01 as
shown in figure 15. After local treatment (SCI +CUR), no significant elevation in TAC
levels was detected when compared with SCI group. Tables are represented in appendix.

3.1.4 Local Curcumin and Diet supplement significantly elevate TAC 7 Days after
SCI.
TAC levels were significantly decreased in SCI + local treatment group (SCI+CUR) when
compared to control group p<0.01 at 7 days after SCI. However, TAC levels were
significantly elevated by local treatment regimen (SCI+CUR) p< 0.05 and by Dietary
supplement group (SCI + Diet) p< 0.01 compared to SCI group as shown in figure 16.
Moreover, TAC levels were significantly elevated by diet supplement when compared to
local treatment regimen p<0.01 as sown in figure 16. Tables are represented in appendix.
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TAC Levels in Spinal Cord Tissue - 1 Day
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Figure 15 : TAC levels in spinal cord tissue 1 day after SCI. TAC levels measured for
Control, SCI, SCI+CUR in homogenized spinal cord tissue. TAC represented as Mm/L. n =
(4-6), all samples were run in duplicate. Error bars are standard deviation.(**p<0.01 vs.
Control group.(One way ANOVA, Dunnett post hoc, Independent t-test)
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TAC Levels in Spinal Cord Tissue - 7 Days
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Figure 16: TAC levels in spinal cord tissue 7 days after SCI. TAC levels measured for
Control, SCI, SCI+CUR and SCI+Diet in homogenized spinal cord tissue. TAC
represented as Mm/L. n = (4-6), all samples were run in duplicate. Error bars are standard
deviation. (**p<0.01 vs.Control, ##p<0.01 vs. SCI group, #p<0.05 vs. SCI group, ɵ
p<0.01vs.SCI+CUR group). (One way ANOVA, Dunnett post hoc).

45

3.2. Effect of Curcumin on Inflammatory Cytokines Expression in Spinal Cord Tissue
To determine the effect of Curcumin on the inflammatory process following SCI, we
measured TNF α and IL-6 levels in spinal cord tissue after local treatment


TNF α levels were measured at 7 days post injury for both local treatment (SCI +
CUR 200 mg/kg) with Curcuma longa extract (Herb pharm, Williams, Oregon) and
dietary supplement regimen (SCI + Diet) (1 day TNF α values to be completed).



IL-6 levels were measured for 1 day and 7 days local treatment (SCI +CUR 200
mg/kg) with Curcuma longa extract (IL-6 levels for Dietary supplement group to be
completed).

3.2.1 Local Curcumin and Diet Supplement Significantly Decrease TNF α Expression
Levels
TNF α levels were measured in rat spinal cord tissue in control, injury and treatment groups
using Enzyme Linked immunosorbent Assay (ELISA). TNF α was measured as Pg/ml.
As shown in figure 17 at 7 days after SCI, TNF α levels were significantly elevated in SCI
group p< 0.01 compared to control group. Upon treatment, TNF α levels were significantly
lower in local treatment (SCI+CUR) and Diet supplement groups (SCI+Diet) compared to
SCI group p<0.01. Tables are represented in appendix.
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TNF α Expression Levels in Spinal Cord Tissue - 7 Days
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Figure 17: TNF α expression levels in spinal cord tissue 7 days after SCI by ELISA. TNF
alpha levels for Control, SCI, SCI+CUR and SCI+Diet in homogenized spinal cord tissue
represented as Pg/ml. n=(4-6),all samples were run in duplicate. Error bars are standard
deviation. **p< 0.01 vs. control, ##p< 0.01 vs SCI. (One way ANOVA, Dunnett post hoc).
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3.2.2. IL-6 Expression Levels 1 Day after SCI and Local Curcumin Application

IL-6 expression was measured in rat spinal cord homogenized tissue samples using ELISA. IL-6 is

expressed as Pg /ml. At 1 day after SCI, IL-6 levels were significantly elevated in SCI and
local Curcumin treatment (SCI+CUR) compared to control group p< 0.01 and p < 0.05
respectively. No significant lowering of IL-6 values was detected upon local treatment (SCI+CUR)
when compared to SCI group at 1 day as shown in figure 18. Tables are represented in appendix.

3.2.3 Local Curcumin Significantly Decreases IL-6 Levels 7 Days after SCI
At 7 days, IL-6 levels were significantly elevated in SCI and local treatment group
(SCI+CUR) compared to control group P<0.01. Upon local treatment, IL-6 levels were
significantly lowered compared to SCI group P< 0.05 as shown in figure 19. Tables are
represented in appendix.
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450
400

**
*

350
IL-6 Pg/ml

300
Control

250

SCI 1 Day

200

SCI+CUR 1Day

150
100
50
0

Figure 18 : IL-6 Expression levels in spinal cord tissue 1 day after SCI measured by
ELISA. IL-6 levels for Control, SCI, SCI+CUR in homogenized spinal cord tissue
represented as Pg/ml. n=(3), all samples were run in duplicate.Error bars are standard
deviation. (*p< 0.05, ** p<0.01 vs. Control group).(One way ANOVA, Dunnett post hoc,
Independent t-test).
48

IL-6 Expression levels in Spinal Cord Tissue - 7 Days
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Figure 19 : IL-6 expression level in spinal cord tissue 7 days after SCI measured by
ELISA. IL-6 for Control, SCI, SCI+CUR and SCI+Diet in homogenized spinal cord tissue
represented as Pg/ml. n=(3), all samples were run in duplicate. Error bars are standard
deviation. (**p<0.01 vs. Control, # p< 0.05 vs SCI group). (One way ANOVA, Dunnett
post hoc, Independent t-test).
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3.3 Neurological Function Evaluation

In our study, behavioral assessment has shown that Curcumin treatment groups exhibit a
trend towards improved functional activity in treatment groups relative to injury groups.
However, our results didn’t evaluate the functional improvements on longer term, yet an
improvement upon injury was noticed when treatment groups were compared to injury
group 7 days after SCI
Thus a complete behavioral assessment was not presented. However, this is a long term
study and since our main goal is to compare between dietary regimen and local regimen we
assume that motor function test starting at 7 days would reflect more reliable data
especially regarding diet supplement regimen. Thus, in order to validate our data we intend
to complete the neurological assessment applying the scoring system between different
groups on longer term to obtain a more descriptive and accurate data on the effect of
Curcumin treatment on neurological function.

3.4 Histology

Spinal cord sections were examined by hematoxylin and eosin staining. Normal spinal
cord sections and spinal cord sections following SCI were examined. Following injury, the
normal spinal cord structure was impaired where both grey matter and white matter were
damaged; pronounced cavitation was detected accompanied by neuronal degeneration.
Normal and injured spinal cord sections are shown in figures 20 and 21 respectively.
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Figure 20 : Hematoxylin and Eosin Staining Sections of Normal spinal cord. Spinal cord
sections around injury were removed dehydrated, embedded in paraffin and cryosectioned
into 5 μm thick sections. The normal tissue shows preserved tissue with the normal
arrangement of the white matter, grey matter and neurons. (Magnification X40)
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Figure 21 : Hematoxylin and Eosin staining for spinal cord tissue following SCI. Spinal
cord tissue was damaged with impairment of both white matter and grey matter with
noticeable cavitation and neuronal degeneration. (Magnification X40)
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CHAPTER 4: DISCUSSION

Spinal cord injury is a debilitating condition characterized by a series of complex series of
events, the primary injury causes tissue damage, axons demyelination, and cell membrane
damage enhancing the initiation of secondary injury cascade (Kwon et al., 2004).
Secondary damage involves multiple events such as ionic imbalance, release of free
radicals, glutamate excitotoxicity, blood-spinal cord barrier damage and inflammation.
These events are mediated and potentiated by glial cells, macrophages and T-lymphocytes
(Anwar et al., 2016). It is well established that reduction of secondary tissue damage is a
prime goal in treating spinal cord injury (Dumont et al., 2001).

The main focus of our study was to study the effects of Curcumin on two of the main
hallmarks of secondary SCI; the inflammatory process and the oxidative damage. Our
second goal was to find if dietary supplement of Curcumin would have a similar role to
direct local application.

Curcumin is a naturally occurring nonsteroidal that manifests an array of beneficial
pharmacological effects as anti-inflammatory, antioxidant, anticarcinogenic and antibacterial functions (Shishodia 2013). Thus detecting a potential role for Curcumin in spinal
cord injury might add a potential tool in ameliorating the damaging cascade of events in
SCI, as well as other CNS conditions thought to be caused by inflammation and oxidative
damages. It has been proposed in several studies that curcumin administration enhances
neuroprotection by decreasing inflammatory response, oxidative stress damage, glial scar
formation and enhancing motor recovery as will be discussed below.

This study focuses on detecting the hypothesized role of Curcumin as a neuroprotective
agent through its anti-inflammatory and an antioxidant effect. The main findings of this
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study were as follows: 1) a significant increase in inflammatory and oxidative markers was
noticed following injury, MDA, TNF α and IL-6 respectively. 2) Elevation in TAC levels
following treatment specifically by 7 days. 3) Curcumin local treatment regimen showed an
anti-inflammatory and antioxidant potential 4) Dietary curcumin supplement showed a
beneficial effect; however, we conclude that both regimens need further modification.

Following SCI, a milieu is developed that shifts the balance pro-oxidant/ antioxidant
towards oxidative stress (Bains and Hall, 2012). It results from failure of free radicals
scavenging capacity. Free radicals cause lipid peroxidation and protein damage within
spinal neurons, glia and other cells (Fatima et al., 2015). In SCI rat models,
Malondialdehyde (MDA) elevation has been documented following injury (Varija et al.,
2009). MDA is an aldehyde end product of lipid peroxidation in SCI and is regarded as an
evidence of oxidative stress in rat SCI models (Liu et al., 2013, Kim et al., 2014).

In the present study Curcumin showed a noticeable antioxidant effect; however, varied
depending on the treatment regimen applied. After injury, MDA levels were significantly
elevated by 1 day compared to the control group, this is consistent with other studies which
show that ROS generation in rat model is characterized by an elevation in MDA
accompanied with reduction of antioxidant markers as superoxide dismutase (Paterniti et
al., 2009; Liu et al., 2013; Guo et al., 2014). Xu et al. showed that 6 h after spinal cord
compression injury, MDA levels were elevated in a modest; however, a significant manner,
this elevation was also detected by immunohistochemical staining in motor neurons (Xu et
al., 2005)

We noticed that in Curcumin local treatment groups (SCI +CUR 200 mg/kg), MDA levels
were significantly lowered compared to injury groups either at 1 day or 7 days. This is
consistent with other studies where Kavakli et al. reported a decrease in MDA level 24 h in
serum post Curcumin treatment in a weight drop SCI model where Curcumin was given
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200 mg/ kg orally (Kavakli et al., 2011). Sanli et al. reported similar findings following
Curcumin administration 300 mg/kg intraperitoneally (Sanli et al., 2011).

At 7 days we noticed a significant decline in MDA levels following local treatment
compared to injury and control groups. This is not consistent with the findings of Kim and
colleagues, who report a significant elevation in MDA level by 1 week that only lowered
significantly at 2 weeks when compared to vehicle group (Kim et al., 2014). However, their
findings were based on plasma levels and not in cord tissue as our current study. Another
possibility is the difference in the model used where Kim et al used an aneurysm clip
compression SCI model, while we used a hemisection model.

Curcumin Dietary supplement given 7 days before and 7 days after injury, did not affect
MDA levels significantly when compared to 7 days injury group. We assume that the
dietary regimen that we applied was not capable enough of affecting MDA values post
injury. Moreover, Dietary supplement with crude Curcumin was introduced to the animals
ad libitum, thus a variation between the amounts of Curcumin between animals might have
affected the overall effect. Although our goal was to test the potential neuroprotective
effects of Curcumin when used as a dietary supplement, we recommend to avoid such
variability by introducing Curcumin in a consistent and reproducible manner by gavage as
previously described (Reeta et al., 2009; CONEAC et al., 2017).

Total antioxidant capacity (TAC) represents the synergistic effect between different
antioxidants (Valkonen and Kunsi, 1997). At 1 and 7 days, we noticed a significant
decrease in TAC values in all injury and treatment groups when compared to control group
except in the dietary supplement group where higher TAC values were detected. However,
when comparing to injury group 7 days after SCI, both local treatment (200 mg/kg) and
Dietary supplement induced a significant elevation in TAC values compared to 7 days
injury group. Moreover TAC levels in Diet supplement groups were more significantly
elevated when compared to local treatment group.
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We assume that this effect by the Curcumin dose we used (200 mg/kg) was masked at 1
day by the surge of oxidative damage that follows injury; however, by 7 days this surge has
subsided due to the initial treatment and Curcumin treatment possibly had a delayed effect.

Al Rubaei and colleagues detected higher TAC and lower MDA levels in Curcumin treated
groups when compared with H2O2 experimentally induced oxidative stress group in liver
tissue homogenate (Al Rubaei et al., 2014). In a rat inflammation model, oral Curcumin in
carboxy-methylcellulose (150 mg/kg), liver Total antioxidant capacity (TAC) was
increased significantly in Curcumin treatment groups where samples were collected 15 min
to 3h after Curcumin treatment, while serum TAC levels in Curcumin/carboxymethylcellulose group and inflammation were lower than Curcumin only group (CONEAC
et al., 2017).

In this context we have to highlight three main points. First, at 1 day local treatment the
significant decrease in MDA was not accompanied by significant TAC elevation when
compared to injury group. Second, at 7 days local treatment (200 mg/kg) we noticed that
TAC was significantly elevated and MDA was significantly lowered as compared to 1
week injury group. Third, dietary Curcumin supplement elevated TAC significantly;
however, MDA levels were not significantly lowered when compared to SCI group

Regarding the first point, MDA lowering might be attributed to an increased activity of a
certain antioxidant enzyme such as SOD or Catalase which were reported to be elevated by
Curcumin treatment in other SCI models, (Cemil et al., 2010; Kavakli et al., 2011; Kim et
al., 2014) . Hence, MDA might have been affected by a certain enzyme (s) rather than the
total antioxidant capacity in the spinal cord tissue

Following dietary Curcumin supplementation, although TAC levels were significantly
elevated, MDA values were not significantly lowered compared to 1 week injury group.
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We assume that in the dietary supplement group the elevation of TAC was still not enough
to cause MDA lowering, or possibly this elevation in TAC levels was not enough to induce
the expression of antioxidant enzymes that affects MDA levels. Another possibility is that
crude forms of Curcumin have a mix of active ingredients that induce various biochemical
effects, therefore we recommend using a pure form of Curcumin extract, or other Curcumin
derivatives such as (CNB-001; 500 ppm) should be considered. This derivative is more
stable and enhances neuroprotection as well (Liu et al., 2008; Wu et al., 2011).

A proposed mechanism of Curcumin is that it enhances the activation of nuclear factor
erythroid 2-related factor (Nrf2). Elevation in the level of antioxidant enzymes is regulated
through antioxidant response element (ARE) that is present in the regulatory region of
genes of antioxidant enzymes (Nguyen et al., 2003). ARE is an enhancer of a number of
phase II antioxidant enzyme genes as Hemeoxygenase, reduced nicotinamide adenine
dinucleotide phosphate quinine oxidoreductase and glutamate cysteine ligase (Wilson,
1997). When Nrf2 dissociates from kelch-like ECH associated protein 1 (keap1), it is
translocated to the nucleus and binds to ARE enhancing the transcription of downstream
target genes (Motohashi and Yamamoto 2004).

A study by Jiang and colleagues was the first to report the effect of Curcumin on Nrf2 in
astrocytes, demonstrating that Curcumin enhanced phase II enzymes induction in Nrf2 +/+
astrocytes where this effect was not evident in Nrf2 -/- astrocytes suggesting that Curcumin
enhances Nrf2 cytoprotective role in astrocytes. Moreover, Curcumin inhibited reactive
oxygen species (ROS) in Nrf +/+ Astrocytes and not in Nrf -/- Astrocytes. They propose
that this effect can add a lot to Curcumin therapeutic value especially as it can be a part of
human diet or daily supplement with low toxicity (Jiang et al., 2011).

Jin et al. also demonstrated that Curcumin (IP injections 100mg/kg) enhanced of Nrf2
activity in SCI vascular clip compression model reduced locomotor impairment, apoptosis
and spinal cord edema (Jin et al., 2014).
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Other markers may also be used to evaluate oxidative stress following SCI and treatment
efficacy, such as superoxide dismutase (SOD) (Kavakli et al., 2011) and hemeoxygenase
(HO-1) (Diaz-Ruiz., 2013). The main identified free radicals are: superoxides (O2°--),
hydroxyl radical (° OH), hydrogen peroxide (H2O2), Peroxynitrite (ONOO -) and nitric
oxide (°NO) (Yang et al., 2013) where mainly the superoxide (Liu et al., 1998) and
hydroxyl radical (Bao and Liu, 2004) are the most damaging and play the main role within
the other ROS following SCI. They are produced by a complex system of enzymes in both
microglia and immune cells as: nicotinamide-adenine dinucleotide phosphate (NADPH)
oxidase, xanthine oxidase and cyclooxygenase (Bains and Hall, 2012).

Levels of TNFα are elevated following SCI, reaching its peak within one hour after
primary injury (Dinomais et al., 2009). It is released faster than other inflammatory
cytokines (Feldman, 2008) and it activates several other cytokines and growth factors
release as well as immune cells recruitment. This chief role made TNF α an attractive target
in inflammatory conditions including SCI (Esposito and Cuzzocrea, 2011). Studies suggest
a dual role of TNFα. For instance, it is suggested that it might exert deleterious effects in
acute phase versus beneficial effect in chronic phase after SCI (Chi et al., 2010) or exerting
anti-apoptotic effect through TNFR-NF𝛋B signal transduction pathway (Kim et al., 2001).
TNF α is secreted by microglia and it stimulates glutamate release which in turn through
metabotropic glutamate receptors enhances more TNFα release. Consequently, it acts on
astrocytes inducing glutamate release and upregulating its levels consequently. Due to this
excitatory elevation, calcium entry is elevated causing excitotoxicity and neuronal death,
thus TNF α links neuro-inflammation and excitotoxic effects (Olmos and Lladó, 2014).
Initially TNFα is synthesized as transmembrane protein where its extracellular domain is
cleaved by matrix metalloprotease TNFα converting enzyme into the soluble form where
TNFR1 signaling activates a number of transduction pathways as: JNK, NF- 𝛋B, ERK and
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p38 MAPK (Byun et al., 2012; Olmos and Lladó, 2014) which makes it somehow
ambiguous to clearly define which of them impacts TNF α expression (Olmos and Lladó,
2014). For instance, a study reported that TNF α expression was prevented through
inhibition of MEK/ERK pathway. They also showed that NF-𝛋B binding to DNA which is
initially activated by interferon gamma (IFN Ɣ) is completely dependent on TNFα release
via MEK/ERK pathway in BV-2 microglial cell line (Mir et al., 2009). NF-𝛋B pathway
regulates promoters of cytokines producing genes as TNFα, IL-6 and IL-1β (Hang et al.,
2004). This cascade amplifies initial inflammation and aggravates consequences in SCI
following the initial trauma (Ni et al., 2015).
The production of IL-6 is in part modulated by many factors as IL-1b and TNFα. IL-6
production was correlated with glial scar formation (Brunello et al., 2000). IL-6 knockout
caused astrogliosis suppression (Klein et al., 1997). Besides, following SCI noticeable
impedance of axonal growth was detected in mice with increased IL-6 signals (Lacroix et
al., 2002).
In the present study, TNFα levels were measured at 7 days in all groups (control, SCI,
SCI+ local treatment and SCI+ Dietary supplement). TNF α levels were significantly
elevated at 7 days injury in SCI group compared to control group. Further analysis is
planned to evaluate 1 day expression across different groups.

IL-6 expression was significantly elevated in all groups either SCI (1 day and 7 days) or
SCI +local treatment 200 mg/kg at 1 day and 7 days when compared to control group.
However, data regarding Dietary supplement is not represented for IL-6 and yet to be
completed.

The present data is consistent with previous reports that demonstrated alteration in the
levels of inflammatory cytokines following SCI. In an SCI clamp model, serum levels of
TNFα, IL-6, IL-10 and IL-1a gradually increased at 24h reaching peak at 3 days. Pro59

inflammatory cytokine expression started lowering at day 7, although shown to remain
significantly higher than control group, and stabilizing at day 28 (Geng et al., 2015). In an
SCI weight drop contusion model, IL-6 receptor expression quantified by western blot was
increased 8 fold within 12 hours following injury when compared to before injury (Okada
et al., 2004). In an aneurysm clip compression model showed that inflammatory cytokines
including TNFα, NF-𝛋B and IL-1β increased at 1 hour after injury and peaking at 12 hours
SCI (Yuan et al., 2015). Guo and colleagues also showed an elevation in TNFα and IL-6
mRNA levels at 2h and 6 h respectively following spinal cord contusion, as well as, a
significant increase in the TNF α and IL-6 protein levels at 24 hours following SCI (Guo et
al., 2014).

This documented variability in peak times may be due to differences in severity of injury
between different SCI models. The first study to compare severity dependent expression of
IL-1β, IL-6 and TNFα following SCI, used a graded SCI contusion model. On the gene
level, IL-6 and TNFα mRNA levels were increased at 1, 3 h and peaked at 6 h post injury
returning to baseline levels at 1 d flowing severe injury, while these levels were
significantly lower in the mild injury group. On the protein level, the cytokines including
TNFα and IL-6 showed a marked but transient increase following severe SCI while in the
mild injury group no cytokines were detected by western blotting (Yang et al., 2005).

The effects of Curcumin have been well documented; Chen et al. demonstrated that
Curcumin treatment reduced IL-1β mRNA expression in astrocyte culture with no change
in TNFα expression, while in microglia pretreatment with Curcumin decreased the elevated
IL-1β and TNFα significantly (Chen et al., 2015). Another study showed that following
contusion SCI TNFα is localized in the cytoplasm of the anterior horn neurons of the spinal
cord and that the number of TNFα positive cells in gray matter was significantly elevated
24 h and at 3 d post injury. TNFα expression was significantly elevated at 3d and 5d
(Zhang et al., 2015).
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In our study we detected changes in TNF α and IL-6 in spinal cord tissue samples as an
indicator for the inflammatory process following SCI hemisection model. After Curcumin
administration, TNFα levels were significantly decreased in SCI + local (200 mg/kg) and
SCI + diet groups when compared to 7 days SCI group. Furthermore at 7 days, IL-6 levels
were significantly decreased Curcumin local treatment when compared to SCI group;
however, at 1 day local treatment did not show a significant decrease. This might be due
the strong recruitment of inflammatory cytokines by immune cells that might mask
Curcumin effect. Nonetheless, Curcumin significantly lowered IL-6 level by 7 days, this
might be explained by a delayed effect of curcumin that was not manifested at 1 day.

Machova et al used a single local dose of Curcumin followed by daily IP administration of
Curcumin daily for 28 days following SCI using a balloon compression model TNFα levels
were only significantly decreased at days 1 and 14.

They demonstrated a transient

elevation of TNF α levels between day 3 and 14; however, they assumed that it might be
due to activation of the immune response cells which when stabilized TNFα levels
decreased. They also proposed that Curcumin dose might have not been effective
(Machova et al., 2015). They also demonstrated that IL-6 levels were significantly elevated
upon treatment with curcumin when compared to vehicle control at days 14 and 28
(Machova et al., 2015). It is worth mentioning that Machova et al. study used a different
SCI model and a different Curcumin treatment regimen than the regimens we used in the
present study.

Machova et al. 2015 also showed that following treatment, no alteration was found in IL-6
levels at days 1, 3, 7 and 10; however, its level was increased by days 14 and 28. They
proposed that Curcumin might act more effectively in early stages or that its effect is for a
distinct period of time, but their detection window was till 28 days so the early phase in
their study was 7 days which is regarded as the delayed phase in our current study.
However, we believe that further investigation is needed to validate IL 6 changes at
different time points.
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Yuan et al. demonstrated that TNFα besides other inflammatory cytokines were elevated
significantly at the gene and protein levels following SCI through aneurysm clip
compression where Curcumin was given as 300 mg /kg once daily for 7 days. The
elevation at the protein level was documented as soon as 1 hour following injury with a
peak elevation at 12 hours post injury followed by a decline; however, they reported that
the expression remained high in their therapeutic detection window which was 72 hours. In
their study they correlated these high cytokine levels by a strong inflammatory response in
acute SCI. Moreover, the authors suggested a correlation between the higher cytokine
levels including TNFα, IL-1β and NF- κB in the simple injury group and a larger glial scar
area aggravating secondary damage and tissue necrosis (Yuan et al., 2015).
Another study using vascular clip compression SCI model, showed that TNFα, IL-1β and
IL-6 were elevated by 257.9%, 229.0% and 296.3% increase respectively compared to
sham group. The authors suggested a mechanism behind this elevation, they showed that
following SCI, an increased expression of toll like receptor 4 (TLR4) on the gene and
protein level followed by upregulation of NF-kB was documented. In turn, this
upregulation potentiates the activation of the inflammatory cytokines as TNFα which in
turn activates NF-kB. Thus a positive feedback mechanism is initiated amplifying
inflammation and exacerbating damage following SC I (Ni et al., 2015). Hence, they
proposed that Curcumin therapeutic effect is due to modulation of TLR4/NF-𝛋B
inflammatory pathway and (Ni et al., 2015).

In a vascular clip compression model, Jin et al. showed that at 72 hours following injury,
TNFα, IL-1β and IL-6 concentrations were significantly lower in the Curcumin treatment
group when compared to the SCI group. Curcumin was administered in a similar dose to Ni
et al. (intraperitoneally as 100 mg/kg in PBS including 1% DMSO). Jin and Colleagues
demonstrated that curcumin administration up-regulated Nrf2 activity while NF-𝛋B activity
was down regulated. They proposed that Curcumin beneficial effect was due to enhancing
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the activity of Nrf2, decreasing NF-𝛋B and hence decreasing the activity of the
downstream inflammatory cytokines (Jin et al., 2014).

Cytokines specific mechanism of action in neurodegeneration is considered complex and
still unclear. They can either act directly on neurons or indirectly through affecting blood
flow, glia or brain vasculature. Cytokines can act on many levels exerting multiple actions
on different cells eventually causing excess calcium release, apoptosis, enhancing calcium
uptake and free radical production (Allan and Rothwell, 2001).

In our study, neurological assessment has shown that Curcumin treatment groups exhibit a
trend towards improved functional activity in treatment groups relative to injury groups.
However, our results didn’t evaluate the functional improvements on longer term , yet an
improvement upon injury was noticed when treatment groups were compared to injury
group 7 days after SCI
A complete behavioral assessment was not presented as well. However, this is a long term
study and since our main goal is to compare between dietary regimen and local regimen we
assume that motor function test starting at 1 week would reflect more reliable data
especially regarding diet supplement regimen .For instance another study performed the
behavioral assessment at postoperative days 21 and 42 (Holly et al., 2012).

Several studies show functional improvement following Curcumin treatment in various SCI
models. Liu et al. performed a neurological assessment test on ischemia/ reperfusion (I/R)
SCI model 48 hours following reperfusion. They showed that after Curcumin treatment,
although neurological score was lower than sham group yet it was higher than that of the
I/R group significantly (Liu et al., 2013). Ni et al. used Basso, Beattie and Bresnahan
(BBB) locomotor scale to assess forelimb-hindlimb coordination, hind limb movements
and whole body movements as well. By 72 h following SC compression injury, BBB score
was nearly zero; however, after Curcumin treatment 100 mg/kg IP the score was
significantly increased (Ni et al., 2015). In a left hemisection SCI model, daily Curcumin
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treatment (40 mg/kg) starting 1 day before surgery and continued until 6 days, showed that
Curcumin treatment was accompanied by improved BBB score of the affected hind limb on
days 3 and 7 (Lin et al., 2011). Yuan et al also reported a dose effect correlation where
higher Curcumin concentrations caused more improvement of functional recovery on the
BBB score when compared with methylprednisolone (MP) or with the simple injury group
starting from week one till week 8 (Yuan et al., 2015).

Regarding the scope of our study, which is comparing the dietary regimen with local
treatment regimen, a long term behavioral assessment should be considered to reliably
evaluate if the regimens used would give a sustained motor function improvement or not.
For instance Yuan et al. evaluated the effect of the given curcumin treatment from week 1
till week 8 (Yuan et al., 2015). Besides, Holly et al. compared different groups for
behavioral assessment on postoperative day 21 and 42 where they were detecting the effect
of docosahexaenoic acid-curcumin (DHA-Cur) diet on enhancing neuroprotection in
cervical spondylotic myelopathy (CSM) rat model (Holly et al., 2012).

Potential limitations of our study could be the dietary regimen using crude turmeric which
only contains 3-5 % Curcuminoids 60% of which is Curcumin (Gupta et al., 2013). Thus
using a more stable and efficacious form as CNB-001 used by Wu et al. study might have
represented clearer results. Another limitation was not looking at time points between 1 day
and 7 days as some markers in our study have shown a change by 7 days thus their
fluctuation pattern before 7 days should be investigated. Moreover, time points beyond 7
days should be considered as well for investigating the sustainability of Curcumin either
biologically or regarding on motor function assessment following treatment.

In another study, Curcumin was applied locally then systemically throughout the
experiment (Machova et al., 2015). We should consider daily dosing or a sustained release
formulation especially that Curcumin is rapidly degraded. However, we were trying to
monitor if this initial dose would affect the oxidative and inflammatory processes
64

especially that it was applied locally and immediately post injury thus we assumed a local
treatment regimen would be more effective than the oral or the systemic regimen.

Thus, we believe that Curcumin has a great potential in CNS injury due its potential as an
anti-inflammatory and anti-oxidant, although longer term investigation are necessary to
evaluate the sustainability of Curcumin effects in CNS injury.
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CONCLUSION

The results presented here reflect a role of Curcumin in alleviating oxidative damage and
inflammation following SCI via lowering MDA, TNF α and IL-6 and elevating TAC. At 7
days following treatment we noticed that Curcumin exerted better effect; however, we
believe that further modifications to our studies should be implemented in future
investigation. Overall in our current model, local treatment regimen (200 mg / kg)
immediately after injury gave better results than Curcumin as a dietary supplement,
suggesting that although Curcumin as a dietary supplement may have beneficial effects in
general by increasing TAC; however, these benefits are not enough to reverse or reduce the
inflammatory process and parenteral administration of Curcumin is needed.
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FUTURE RECOMMENDATIONS
Cumulative studies demonstrate a beneficial therapeutic potential of Curcumin following
SCI (Cemil et al., 2010; Kavakli et al., 2011; Machova et al., 2015; Yuan et al., 2015). Our
study has shown that curcumin might alleviate the consequences of oxidative and
inflammatory processes which are two main hallmarks of secondary spinal cord injury.

Many mechanisms have been proposed for its beneficial role yet a verification of the
mechanism through which it affects its targets has not been fully described or validated
where some recent reports have described Curcuminoids as pan assay interference
compounds (PAINS) (Baell and Walters 2014). Thus understanding Curcumin and its
mechanism of action towards its targets should be a priority in the ongoing research
evaluating its efficacy and potential.

To get results that are more descriptive for the role of Curcumin in SCI we recommend that
a new Curcumin delivery system as liposomal curcumin should be used for local treatment
regimen. Liposomal Curcumin formulation demonstrated a remarkable enhancement of
curcumin bioavailability in cells.

For the dietary regimen we recommend the use of CNB-001 as used by Wu et al. (2011)
that would enhance the stability and absorption of curcumin in the biological system. In the
present study we measured the total antioxidant capacity; in future investigation we would
recommend measuring antioxidant enzymes and investigate which of them is affected by
Curcumin treatment following injury as SOD which was found to be elevated by Curcumin
(Kavakli et al., 2011; Liu et al., 2013).

Long term behavioral assessment using motor (inclined plane test), sensory (withdrawal
reflex test) and sensorimotor tests (Grid walk test) is a future direction regarding our study
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to detect if Curcumin dietary supplement or local treatment regimen would manifest
sustained motor improvement.

Measuring markers for astrogliosis and axonal sprouting as GFAP and GAP 43 (Growth
Associated Protein 43) respectively is an important future investigation for the effect of
Curcumin on the environment surrounding the injury site and whether Curcumin will
contribute to enhancement of neurological recovery.

Detecting time points before 1 day and between 1 day and 7 days would reflect a clearer
idea on Curcumin’s effect in SCI. However, in this study our main scope was comparing
between the dietary and local regimens so 7 days and beyond, in our view was suitable for
the dietary supplement effect to be investigated.
One of the major obstacles impeding Curcumin’s progress is its low bioavailability, rapid
metabolism and poor absorption as well (Kong 2013). For this purpose Curcumin nanoformulations have been developed to enhance its bioavailability and efficacy. This included
liposomes, micelles, nanocrystals and others (Rachmawati et al., 2013).

Our results shows that Curcumin might exhibit an antioxidant and anti-inflammatory
potential in SCI. Local treatment regimen demonstrated better results than diet supplement;
however, we believe that further investigation is needed to unravel the mechanism by
which Curcumin acts towards its targets.
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APPENDIX
1) MDA 1 day:
Results are expressed as mean ± standard deviation
Sig. = Significant , Sign.= Significance, N.S.= Not significant
Table 1 : One way ANOVA
1 Day

Marker

Control

MDA

414.83±126.8

SCI

SCI+CUR

835.67±61.5

p-value

493.60±75.2

0.004

Sig.
Significant

Statistical test used: One-way ANOVA
p-value ≤ 0.05 considered statistically significant (95% confidence interval).

Table 2: Dunnett Post Hoc to identify variables that made significant change
1 Day

Marker
MDA

Control

SCI

p-value

Sig.

SCI+CUR

p-value

Sig.

414.83±126.8

835.67±61.5

0.003

Significant

493.60±75.2

0.611

N.S

Statistical test used: Dunnett post Hoc test
p-value ≤ 0.05 considered statistically significant different from control (95% confidence interval).

Table 3: Independent t-test
Marker
MDA

1 Day
SCI
835.67±61.5

SCI+CUR

p-value

Sig.

493.60±75.2

0.011

Significant

Statistical test used: Independent t-test
p-value ≤ 0.05 considered statistically significant different (95% confidence interval).
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2) MDA 7 days
Table 4: One way ANOVA
7 Days

Marker

Control

MDA

SCI

414.83±126.78

SCI+CUR

480.73±121.14

SCI+DIET

245.38±36.88

Sig.

p-value

406.32±145.71

0.047

Significant

Statistical test used: One-way ANOVA
p-value ≤ 0.05 considered statistically significant (95% confidence interval).

Table 5: Dunnett Post Hoc to identify variables that made significant change
7 Days
Marker
MDA

Control

SCI

414.83±126.7

480.73±121.1

8

4

pvalue

Sig.

0.702

N.S

SCI+CUR

pvalue

Sig.

0.131

N.S

245.38±36.8

SCI+DIET
406.32±145.7

8

pvalue

Sig.

0.999

N.S

1

Statistical test used: Dunnett post Hoc test
p-value ≤ 0.05 considered statistically significant different from control (95% confidence interval).

Table 6: Dunnett Post Hoc to identify variables that made significant change
7 Days
SCI

Marker

SCI+CUR
pvalue

Sig.

480.73±121.14

-----

-----

SCI+CUR

245.38±36.88

0.014

SCI+DIET

406.32±145.71

0.563

Mean ±SD

MDA
SCI

SCI+DIET

pvalue

Sig.

480.73±121.14

0.014

Sign.

Sign.

245.38±36.88

-----

N.S

406.32±145.71

0.137

480.73±121.14

Mean ±SD

pvalue

Sig.

480.73±121.14

0.563

N.S

-----

245.38±36.88

0.137

N.S

N.S

406.32±145.71

-----

-----

245.38±36.88

406.32±145.71

Statistical test used: Dunnett post Hoc test
p-value ≤ 0.05 considered statistically significant different (95% confidence interval).
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Mean ±SD

3) TAC 1 day
Table 7: One way ANOVA
Marker

1 Day
Control

TAC

5.66±0.94

SCI

SCI+CUR

0.46±0.21

Sig.

p-value

0.54±0.13

Significant

0.0001

Statistical test used: One-way ANOVA
p-value ≤ 0.05 considered statistically significant (95% confidence interval).

Table 8: Dunnett Post Hoc to identify variables that made significant change
1 Day

Marker

Control

TAC

SCI

5.66±0.94

0.46±0.21

Sig.

SCI+CUR

Significant

0.54±0.13

p-value
0.0001

Sig.

p-value
0.0001

Significant

Statistical test used: Dunnett post Hoc test
p-value ≤ 0.05 considered statistically significant different from control (95% confidence interval).

Table 9: Independent t-test

Marker
TAC

1 Day
SCI
0.46±0.21

SCI+CUR

p-value

Sig.

0.54±0.13

0.577

Not significant

Statistical test used: Independent t-test
p-value ≤ 0.05 considered statistically significant different (95% confidence interval).
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4) TAC 7 days
Table 10: One way ANOVA

Marker

7 Days
Control

TAC

SCI

5.66±0.94

SCI+CUR

1.30±0.51

SCI+DIET

3.06±1.40

Sig.

p-value

5.81±0.83

Significant

0.0001

Statistical test used: One-way ANOVA
p-value ≤ 0.05 considered statistically significant (95% confidence interval).

Table 11: Dunnett Post Hoc to identify variables that made significant change
7 Days
Marker
TAC

Control

SCI

pvalue

Sig.

SCI+CUR

pvalue

Sig.

5.66±0.94

1.30±0.51

0.0001

Sign.

3.06±1.40

0.002

Sign.

SCI+DIET
5.81±0.83

pvalue

Sig.

0.992

N.S

Statistical test used: Dunnett post Hoc test
p-value ≤ 0.05 considered statistically significant different from control (95% confidence interval).

Table 12: Dunnett Post Hoc to identify variables that made significant change
7 Days
SCI

Marker
Mean ±SD

TAC

SCI+CUR
pvalue

Sig.

1.30±0.51

Mean ±SD

pvalue

SCI+DIET
Sig.

3.06±1.40

Mean ±SD

pvalue

Sig.

5.81±0.83

SCI

1.30±0.51

-----

-----

1.30±0.51

0.024

Sign.

1.30±0.51

0.0001

Sign.

SCI+CUR

3.06±1.40

0.024

Sign.

3.06±1.40

-----

-----

3.06±1.40

0.003

Sign.

SCI+DIET

5.81±0.83

0.0001

Sign.

5.81±0.83

0.003

Sign.

5.81±0.83

-----

-----

Statistical test used: Dunnett post Hoc test
p-value ≤ 0.05 considered statistically significant different (95% confidence interval).
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5) TNF α 7 days
Table 13: One way ANOVA

7 Days

Marker

Control

TNF alpha

SCI

17.52±1.94

SCI+CUR

56.09±7.53

SCI+DIET

18.29±3.76

Sig.

p-value

27.17±5.50

Significant

0.0001

Statistical test used: One-way ANOVA
p-value ≤ 0.05 considered statistically significant (95% confidence interval).

Table 14: Dunnett Post Hoc to identify variables that made significant change
7 Days
Marker
TNF alpha

Control

SCI

pvalue

Sig.

SCI+CUR

pvalue

Sig.

SCI+DIET

pvalue

Sig.

17.52±1.94

56.09±7.53

0.0001

Sign.

18.29±3.76

0.994

N.S

27.17±5.50

0.067

N.S

Statistical test used: Dunnett post Hoc test
p-value ≤ 0.05 considered statistically significant different from control (95% confidence interval).

Table 15: Dunnett Post Hoc to identify variables that made significant change
7 Days
SCI

Marker
Mean ±SD

TNF alpha
SCI

SCI+CUR
pvalue

Sig.

56.09±7.53

Mean ±SD

pvalue

SCI+DIET
Sig.

18.29±3.76

Mean ±SD

pvalue

Sig.

27.17±5.50

56.09±7.53

-----

-----

56.09±7.53

0.0001

Sign.

56.09±7.53

0.0001

Sign.

SCI+CUR

18.29±3.76

0.0001

Sign.

18.29±3.76

-----

-----

18.29±3.76

0.114

N.S

SCI+DIET

27.17±5.50

0.0001

Sign.

27.17±5.50

0.114

N.S

27.17±5.50

-----

-----

Statistical test used: Dunnett post Hoc test
p-value ≤ 0.05 considered statistically significant different (95% confidence interval).
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6) IL-6 1 day

Table 16: One way ANOVA
Marker

1 Day
Control

IL-6

SCI

53.23±5.55

SCI+CUR

327.99±58.93

Sig.

p-value

244.81±90.51

Significant

0.009

Statistical test used: One-way ANOVA
p-value ≤ 0.05 considered statistically significant (95% confidence interval).

Table 17: Dunnett Post Hoc to identify variables that made significant change
Marker
IL-6

1 Day
Control

SCI

53.23±5.55

327.99±58.93

Sig.

SCI+CUR

Significant

244.81±90.51

p-value
0.008

Sig.

p-value
0.019

Significant

Statistical test used: Dunnett post Hoc test
p-value ≤ 0.05 considered statistically significant different from control (95% confidence interval).

Table 18: Independent t-test
Marker
IL-6

1 Day
SCI
327.99±58.93

SCI+CUR

p-value

Sig.

244.80±90.51

0.315

Not significant

Statistical test used: Independent t-test
p-value ≤ 0.05 considered statistically significant different (95% confidence interval).
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7) IL-6 7 days
Table 19: One way ANOVA
7 Days

Marker

Control

IL-6

53.23±5.55

SCI

SCI+CUR

349.56±43.17

Sig.

p-value

214.18±82.07

Significant

0.0001

Statistical test used: One-way ANOVA
p-value ≤ 0.05 considered statistically significant (95% confidence interval).

Table 20: Dunnett Post Hoc to identify variables that made significant change
Marker
IL-6

7 Days
Control
53.23±5.55

SCI

p-value

Sig.

SCI+CUR

349.56±43.17

0.0001

Significant

214.18±82.07

Sig.

p-value
0.009

Significant

Statistical test used: Dunnett post Hoc test
p-value ≤ 0.05 considered statistically significant different from control (95% confidence interval).

Table 21: Independent t-test
Marker
IL-6

7 Days
SCI
349.56±43.17

SCI+CUR
214.18±82.07

Statistical test used: Independent t-test
p-value ≤ 0.05 considered statistically significant different (95% confidence interval).
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p-value

Sig.

0.020

Significant
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99

100

101

102

103
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